

The Impact of Mutations in SARS-CoV-2 Spike on Viral

Cell

182, 1284-1294.e9

DOI: [10.1016/j.cell.2020.07.012](https://doi.org/10.1016/j.cell.2020.07.012)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ACE2 enhance viral infection or viral infection aggravate the underlying diseases. Computational and Structural Biotechnology Journal, 2020, 18, 2100-2106.	1.9	6
2	Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nature Protocols, 2020, 15, 3699-3715.	5.5	291
3	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell, 2020, 183, 1024-1042.e21.	13.5	1,195
4	Chemosensory Dysfunction in COVID-19: Integration of Genetic and Epidemiological Data Points to D614G Spike Protein Variant as a Contributing Factor. ACS Chemical Neuroscience, 2020, 11, 3180-3184.	1.7	59
5	Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. Trends in Immunology, 2020, 41, 1006-1022.	2.9	79
6	Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends in Immunology, 2020, 41, 1100-1115.	2.9	794
7	Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. Cell Host and Microbe, 2020, 28, 867-879.e5.	5.1	316
8	No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. Nature Communications, 2020, 11, 5986.	5.8	260
9	Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. Science Translational Medicine, 2020, 12, .	5.8	203
10	The Potential Role of Osteopontin and Furin in Worsening Disease Outcomes in COVID-19 Patients with Pre-Existing Diabetes. Cells, 2020, 9, 2528.	1.8	22
11	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduction and Targeted Therapy, 2020, 5, 282.	7.1	149
12	Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. Frontiers in Molecular Biosciences, 2020, 7, 605236.	1.6	159
13	SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature, 2020, 588, 682-687.	13.7	1,346
14	SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science, 2020, 370, 1464-1468.	6.0	808
15	Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. Journal of Virology, 2020, 94, .	1.5	116
16	Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nature Reviews Immunology, 2020, 20, 727-738.	10.6	107
17	Genetic Spectrum and Distinct Evolution Patterns of SARS-CoV-2. Frontiers in Microbiology, 2020, 11, 593548.	1.5	44
18	Evolutionary Analysis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reveals Genomic Divergence with Implications for Universal Vaccine Efficacy. Vaccines, 2020, 8, 591.	2.1	3

#	ARTICLE	IF	CITATIONS
19	High-Density Amplicon Sequencing Identifies Community Spread and Ongoing Evolution of SARS-CoV-2 in the Southern United States. <i>Cell Reports</i> , 2020, 33, 108352.	2.9	38
20	The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. <i>Frontiers in Immunology</i> , 2020, 11, 576622.	2.2	317
21	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. <i>Cell</i> , 2020, 183, 1367-1382.e17.	13.5	420
22	Prevalence of Chemosensory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic Differences. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2944-2961.	1.7	189
23	Low genetic diversity may be an Achilles heel of SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24614-24616.	3.3	94
24	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <i>Science</i> , 2020, 370, 950-957.	6.0	504
25	Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. <i>Cell</i> , 2020, 183, 1013-1023.e13.	13.5	227
26	Profiling and characterization of SARS-CoV-2 mutantsâ€™ infectivity and antigenicity. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 185.	7.1	33
27	A genetic barcode of SARS-CoV-2 for monitoring global distribution of different clades during the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2020, 100, 216-223.	1.5	43
28	Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. <i>Clinical Infectious Diseases</i> , 2021, 73, e2946-e2951.	2.9	647
29	Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. <i>Neuroscientist</i> , 2021, 27, 582-603.	2.6	238
30	Infectivity of SARS-CoV-2: there Is Something More than D614G?. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 574-577.	2.1	44
31	SARS-CoV-2 Spike Alterations Enhance Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 Virus. <i>Viruses</i> , 2020, 12, 1465.	1.5	35
32	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). <i>Frontiers in Immunology</i> , 2020, 11, 571481.	2.2	48
33	COVID-19: Coronavirus Vaccine Development Updates. <i>Frontiers in Immunology</i> , 2020, 11, 602256.	2.2	143
34	Multiple Introductions Followed by Ongoing Community Spread of SARS-CoV-2 at One of the Largest Metropolitan Areas of Northeast Brazil. <i>Viruses</i> , 2020, 12, 1414.	1.5	47
35	Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. <i>MAbs</i> , 2020, 12, 1854149.	2.6	126
36	Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis. <i>Nature Communications</i> , 2020, 11, 6272.	5.8	183

#	ARTICLE	IF	CITATIONS
37	The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9309.	1.8	27
38	Recent updates on COVID-19: A holistic review. <i>Heliyon</i> , 2020, 6, e05706.	1.4	16
39	Massive dissemination of a SARS-CoV-2 Spike Y839 variant in Portugal. <i>Emerging Microbes and Infections</i> , 2020, 9, 2488-2496.	3.0	20
40	Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2. <i>International Immunopharmacology</i> , 2021, 90, 107172.	1.7	23
41	Phylogenetic analysis of SARS-CoV-2 in the first few months since its emergence. <i>Journal of Medical Virology</i> , 2021, 93, 1722-1731.	2.5	29
42	Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. <i>Genomics</i> , 2021, 113, 1221-1232.	1.3	126
43	Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity. <i>Briefings in Bioinformatics</i> , 2021, 22, 1239-1253.	3.2	99
44	Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 192-203.	1.0	165
45	High Prevalence of SARS-CoV-2 Genetic Variation and D614G Mutation in Pediatric Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa551.	0.4	26
46	N-Glycan Modification in Covid-19 Pathophysiology: In vitro Structural Changes with Limited Functional Effects. <i>Journal of Clinical Immunology</i> , 2021, 41, 335-344.	2.0	17
47	Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1635-1649.	1.4	14
48	Engineered trimeric ACE2 binds viral spike protein and locks it in a Three-up conformation to potently inhibit SARS-CoV-2 infection. <i>Cell Research</i> , 2021, 31, 98-100.	5.7	76
49	Host-directed editing of the SARS-CoV-2 genome. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 35-39.	1.0	80
50	The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 104-107.	1.0	85
51	Functional importance of the D614G mutation in the SARS-CoV-2 spike protein. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 108-115.	1.0	79
52	An updated and comprehensive review of the antiviral potential of essential oils and their chemical constituents with special focus on their mechanism of action against various influenza and coronaviruses. <i>Microbial Pathogenesis</i> , 2021, 152, 104620.	1.3	106
53	Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. <i>Cell Host and Microbe</i> , 2021, 29, 44-57.e9.	5.1	937
54	Nanozyme chemiluminescence paper test for rapid and sensitive detection of SARS-CoV-2 antigen. <i>Biosensors and Bioelectronics</i> , 2021, 173, 112817.	5.3	195

#	ARTICLE	IF	CITATIONS
55	COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. <i>Journal of Proteome Research</i> , 2021, 20, 139-153.	1.8	14
56	Structural basis of severe acute respiratory syndrome coronavirus 2 infection. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 74-81.	1.5	7
57	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. <i>Biotechnology and Biotechnological Equipment</i> , 2021, 35, 74-102.	0.5	13
58	Spike Glycoprotein and Host Cell Determinants of SARS-CoV-2 Entry and Cytopathic Effects. <i>Journal of Virology</i> , 2021, 95, .	1.5	70
59	SARS-CoV-2 genomic characterization and clinical manifestation of the COVID-19 outbreak in Uruguay. <i>Emerging Microbes and Infections</i> , 2021, 10, 51-65.	3.0	33
62	A facile chemoenzymatic synthesis of SARS-CoV-2 glycopeptides for probing glycosylation functions. <i>Chemical Communications</i> , 2021, 57, 6804-6807.	2.2	10
63	Ultra-large-scale ab initio quantum chemical computation of bio-molecular systems: The case of spike protein of SARS-CoV-2 virus. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1288-1301.	1.9	21
64	Single point mutations can potentially enhance infectivity of SARS-CoV-2 revealed by <i>in silico</i> affinity maturation and SPR assay. <i>RSC Advances</i> , 2021, 11, 14737-14745.	1.7	17
65	AutoVEM2: A flexible automated tool to analyze candidate key mutations and epidemic trends for virus. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 5029-5038.	1.9	4
67	How strong is the evidence that it is possible to get SARS-CoV-2 twice? A systematic review. <i>Reviews in Medical Virology</i> , 2021, 31, 1-12.	3.9	7
68	The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization. <i>Journal of Biological Chemistry</i> , 2021, 296, 100536.	1.6	91
69	Kidney injury molecule-1 is a potential receptor for SARS-CoV-2. <i>Journal of Molecular Cell Biology</i> , 2021, 13, 185-196.	1.5	44
70	COVID-19 vaccines: where we stand and challenges ahead. <i>Cell Death and Differentiation</i> , 2021, 28, 626-639.	5.0	626
71	A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351. <i>MAbs</i> , 2021, 13, 1930636.	2.6	13
72	A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. <i>Cellular and Molecular Immunology</i> , 2021, 18, 318-327.	4.8	270
73	Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multi-epitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. <i>Emerging Microbes and Infections</i> , 2021, 10, 1931-1946.	3.0	11
74	Lentil lectin derived from <i>Lens culinaris</i> exhibit broad antiviral activities against SARS-CoV-2 variants. <i>Emerging Microbes and Infections</i> , 2021, 10, 1519-1529.	3.0	30
75	Bioinformatic and MD Analysis of N501Y SARS-CoV-2 (UK) Variant. <i>IFIP Advances in Information and Communication Technology</i> , 2021, , 1-13.	0.5	1

#	ARTICLE	IF	CITATIONS
76	20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment. <i>Journal of Evidence-based Integrative Medicine</i> , 2021, 26, 2515690X2110261.	1.4	16
77	Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 3799-3809.	1.9	24
81	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021, 591, 639-644.	13.7	1,355
82	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.	2.6	167
84	Developing effective siRNAs to reduce the expression of key viral genes of COVID-19. <i>International Journal of Biological Sciences</i> , 2021, 17, 1521-1529.	2.6	17
85	Insights from genomes and genetic epidemiology of SARS-CoV-2 isolates from the state of Andhra Pradesh. <i>Epidemiology and Infection</i> , 2021, 149, .	1.0	2
89	Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2. <i>Clinical and Translational Immunology</i> , 2021, 10, e1260.	1.7	13
90	Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development. <i>BioMed Research International</i> , 2021, 2021, 1-11.	0.9	15
91	SARS-CoV-2 mutations: the biological trackway towards viral fitness. <i>Epidemiology and Infection</i> , 2021, 149, e110.	1.0	53
92	Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. <i>Annual Review of Microbiology</i> , 2021, 75, 19-47.	2.9	52
93	Transcriptomic Analysis of Respiratory Tissue and Cell Line Models to Examine Glycosylation Machinery during SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 82.	1.5	5
95	Identification of a novel lineage bat SARS-related coronaviruses that use bat ACE2 receptor. <i>Emerging Microbes and Infections</i> , 2021, 10, 1507-1514.	3.0	47
96	D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction. <i>Cell Reports</i> , 2021, 34, 108630.	2.9	263
97	A Review on COVID-19 Diagnosis Tests Approved for Use in Brazil and the Impact on Pandemic Control. <i>Brazilian Archives of Biology and Technology</i> , 2021, 64, .	0.5	1
98	AutoVEM: An automated tool to real-time monitor epidemic trends and key mutations in SARS-CoV-2 evolution. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1976-1985.	1.9	9
99	Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. <i>Viruses</i> , 2021, 13, 134.	1.5	56
100	Structural Mapping of Mutations in Spike, RdRp and Orf3a Genes of SARS-CoV-2 in Influenza Like Illness (ILI) Patients. <i>Viruses</i> , 2021, 13, 136.	1.5	4
101	Statistical Challenges in the Analysis of Sequence and Structure Data for the COVID-19 Spike Protein. <i>Journal of Data Science</i> , 2021, , 314-333.	0.5	4

#	ARTICLE	IF	CITATIONS
103	The role of pseudotype neutralization assays in understanding SARS CoV-2. Oxford Open Immunology, 2021, 2, iqab005.	1.2	20
104	COVID-19 reinfection in the presence of neutralizing antibodies. National Science Review, 2021, 8, nwab006.	4.6	24
105	Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19. Heliyon, 2021, 7, e05951.	1.4	15
106	SARS-CoV-2 Genomic Variation in Space and Time in Hospitalized Patients in Philadelphia. MBio, 2021, 12, .	1.8	27
108	Comments on "Development of a PCR-RFLP method for detection of D614G mutation in SARS-CoV-2". Infection, Genetics and Evolution, 2021, 87, 104661.	1.0	5
109	mRNA vaccines for COVID-19: what, why and how. International Journal of Biological Sciences, 2021, 17, 1446-1460.	2.6	185
110	A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nature Communications, 2021, 12, 288.	5.8	224
111	Triazavirin might be the new hope to fight Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Ceska A Slovenska Farmacie, 2021, 70, 18-25.	0.3	9
116	Severe acute respiratory syndrome coronavirus 2 detected in placentas of 2 coronavirus disease 2019 "positive asymptomatic pregnant women" case report. AJOG Global Reports, 2021, 1, 100001.	0.4	3
118	Chemosensory Dysfunction in Patients with COVID-19: What Do We Learn from the Global Outbreak?. Current Allergy and Asthma Reports, 2021, 21, 6.	2.4	11
120	Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile. Science Advances, 2021, 7, .	4.7	29
121	An On-Line Cross-Sectional Questionnaire to Assess Knowledge of COVID-19 Pandemic among Citizens Tested for the SARS-CoV-2 Virus in Quito and Ibarra, Ecuador. International Journal of Environmental Research and Public Health, 2021, 18, 1691.	1.2	5
122	Phylogenetic analysis in the understanding of the current COVID-19 pandemic and its utility in vaccine and antiviral design and assessment. Human Vaccines and Immunotherapeutics, 2021, 17, 2437-2444.	1.4	7
123	Characterization of Critical Determinants of ACE2 "SARS CoV-2 RBD Interaction. International Journal of Molecular Sciences, 2021, 22, 2268.	1.8	24
124	COVID-19 outbreak in Malaysia: Decoding D614G mutation of SARS-CoV-2 virus isolated from an asymptomatic case in Pahang. Materials Today: Proceedings, 2022, 48, 828-836.	0.9	11
126	The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. ELife, 2021, 10, .	2.8	173
127	Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins. PLoS Pathogens, 2021, 17, e1009282.	2.1	42
129	The challenge of emerging SARS-CoV-2 mutants to vaccine development. Journal of Genetics and Genomics, 2021, 48, 102-106.	1.7	19

#	ARTICLE	IF	CITATIONS
130	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. <i>Cell Reports</i> , 2021, 34, 108699.	2.9	110
132	B cell memory: understanding COVID-19. <i>Immunity</i> , 2021, 54, 205-210.	6.6	102
133	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021, 592, 616-622.	13.7	1,232
135	Worldwide tracking of major SARS-CoV-2 genome haplotypes in sequences of June 1 to November 15, 2020 and discovery of rapid expansion of a new haplotype. <i>Journal of Medical Virology</i> , 2021, 93, 3251-3256.	2.5	4
137	Prolonged evolution of the human B cell response to SARS-CoV-2 infection. <i>Science Immunology</i> , 2021, 6, .	5.6	153
138	SARS-CoV-2 spike D614G change enhances replication and transmission. <i>Nature</i> , 2021, 592, 122-127.	13.7	440
142	SARS-CoV-2 genomics: An Indian perspective on sequencing viral variants. <i>Journal of Biosciences</i> , 2021, 46, 1.	0.5	79
144	Adaptive immunity to SARS-CoV-2 and COVID-19. <i>Cell</i> , 2021, 184, 861-880.	13.5	1,364
148	Comparative Study of Chemosensory Dysfunction in COVID-19 in 2 Geographically Distinct Regions. <i>Ear, Nose and Throat Journal</i> , 2021, , 014556132110001.	0.4	5
149	Insights into biological therapeutic strategies for COVID-19. <i>Fundamental Research</i> , 2021, 1, 166-178.	1.6	2
152	Does COVID-19 Vaccination Warrant the Classical Principle "efein i mi vlapin"? <i>Medicina (Lithuania)</i> , 2021, 57, 253.	0.8	10
153	Mutations in SARS-CoV-2 nsp7 and nsp8 proteins and their predicted impact on replication/transcription complex structure. <i>Journal of Medical Virology</i> , 2021, 93, 4616-4619.	2.5	25
154	A multiplexed, next generation sequencing platform for high-throughput detection of SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 1405.	5.8	33
155	Development of a Colloidal Gold-Based Immunochromatographic Strip for Rapid Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein. <i>Frontiers in Immunology</i> , 2021, 12, 635677.	2.2	19
161	Multiplex bead binding assays using off-the-shelf components and common flow cytometers. <i>Journal of Immunological Methods</i> , 2021, 490, 112952.	0.6	10
165	Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 463-476.e6.	5.1	1,054
168	Variable routes to genomic and host adaptation among coronaviruses. <i>Journal of Evolutionary Biology</i> , 2021, 34, 924-936.	0.8	5
170	Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. <i>PLoS ONE</i> , 2021, 16, e0248348.	1.1	102

#	ARTICLE	IF	CITATIONS
171	Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma. <i>Transfusion</i> , 2021, 61, 1705-1709.	0.8	41
172	A SARS-CoV-2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD-Independent Mechanism**. <i>Angewandte Chemie</i> , 2021, 133, 10367-10373.	1.6	16
173	Detection of the SARS-CoV-2 D614G mutation using engineered Cas12a guide RNA. <i>Biotechnology Journal</i> , 2021, 16, e2100040.	1.8	30
175	Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis. <i>Biomolecules</i> , 2021, 11, 390.	1.8	28
176	Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein. <i>Heliyon</i> , 2021, 7, e06564.	1.4	25
177	The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 632814.	2.2	62
178	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. <i>Science</i> , 2021, 372, 1413-1418.	6.0	468
179	Comprehensive and systemic optimization for improving the yield of SARS-CoV-2 spike pseudotyped virus. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 350-356.	1.8	17
181	A SARS-CoV-2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD-Independent Mechanism**. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 10279-10285.	7.2	106
182	Cyanobacterial natural products as sources for antiviral drug discovery against COVID-19. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-17.	2.0	8
185	Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. <i>Reviews in Medical Virology</i> , 2021, 31, e2231.	3.9	128
186	Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting. <i>Inflammopharmacology</i> , 2021, 29, 343-366.	1.9	9
187	Impact of a New SARS-CoV-2 Variant on the Population: A Mathematical Modeling Approach. <i>Mathematical and Computational Applications</i> , 2021, 26, 25.	0.7	23
189	Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. <i>Cell Host and Microbe</i> , 2021, 29, 477-488.e4.	5.1	700
190	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. <i>Cell</i> , 2021, 184, 1171-1187.e20.	13.5	541
193	1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection. <i>Frontiers in Pharmacology</i> , 2021, 12, 634176.	1.6	28
194	Systematic profiling of SARS-CoV-2-specific IgG epitopes at amino acid resolution. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1067-1069.	4.8	14
195	Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. <i>Stem Cell Reports</i> , 2021, 16, 398-411.	2.3	18

#	ARTICLE	IF	CITATIONS
196	Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. <i>Vaccines</i> , 2021, 9, 243.	2.1	217
197	D614G substitution at the hinge region enhances the stability of trimeric SARS-CoV-2 spike protein. <i>Bioinformatics</i> , 2021, 17, 439-445.	0.2	7
201	Initial Insights Into the Genetic Epidemiology of SARS-CoV-2 Isolates From Kerala Suggest Local Spread From Limited Introductions. <i>Frontiers in Genetics</i> , 2021, 12, 630542.	1.1	11
202	Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. <i>Nature Communications</i> , 2021, 12, 1403.	5.8	65
203	The effect of spike mutations on SARS-CoV-2 neutralization. <i>Cell Reports</i> , 2021, 34, 108890.	2.9	200
204	First Identified Cases of SARS-CoV-2 Variant P.1 in the United States – Minnesota, January 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 346-347.	9.0	23
205	Whole-genome sequencing of SARS-CoV-2 reveals the detection of G614 variant in Pakistan. <i>PLoS ONE</i> , 2021, 16, e0248371.	1.1	34
207	SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3060.	1.8	32
208	A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. <i>ACS Central Science</i> , 2021, 7, 512-533.	5.3	217
210	Web resources facilitate drug discovery in treatment of COVID-19. <i>Drug Discovery Today</i> , 2021, 26, 2358-2366.	3.2	4
211	The 442th amino acid residue of the spike protein is critical for the adaptation to bat hosts for SARS-related coronaviruses. <i>Virus Research</i> , 2021, 295, 198307.	1.1	5
212	The Importance of Glycans of Viral and Host Proteins in Enveloped Virus Infection. <i>Frontiers in Immunology</i> , 2021, 12, 638573.	2.2	61
213	Prevalence of COVID-19 and Possible Antigenic Drifts in SARS-CoV-2 Spike Protein in Kurdistan Region-Iraq. <i>Passer Journal</i> , 2021, 3, 0-0.	0.1	0
215	Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication. <i>Cells</i> , 2021, 10, 1052.	1.8	26
216	Biosensing Detection of the SARS-CoV-2 D614G Mutation. <i>Trends in Genetics</i> , 2021, 37, 299-302.	2.9	22
217	Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein. <i>PLoS ONE</i> , 2021, 16, e0250780.	1.1	66
218	SARS-CoV-2 within-host diversity and transmission. <i>Science</i> , 2021, 372, .	6.0	278
219	SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. <i>Cell</i> , 2021, 184, 2362-2371.e9.	13.5	332

#	ARTICLE	IF	CITATIONS
220	Emergence of a Novel SARS-CoV-2 Variant in Southern California. JAMA - Journal of the American Medical Association, 2021, 325, 1324.	3.8	306
222	The Yin and Yang of SARS-CoV-2 Mutation and Evolution. Mayo Clinic Proceedings, 2021, 96, 863-865.	1.4	4
223	Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase. Expert Opinion on Drug Discovery, 2021, 16, 1-15.	2.5	6
225	Practicability of serological assays for upscaling COVID-19 laboratory testing in Africa. Journal of Global Health, 2021, 11, 03038.	1.2	0
226	Bioinformatic prediction of immunodominant regions in spike protein for early diagnosis of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). PeerJ, 2021, 9, e11232.	0.9	5
228	Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies. Journal of Physical Chemistry B, 2021, 125, 4596-4619.	1.2	60
229	Geographical Variations in Host Predisposition to COVID-19 Related Anosmia, Ageusia, and Neurological Syndromes. Frontiers in Medicine, 2021, 8, 661359.	1.2	14
230	Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. Angewandte Chemie, 2021, 133, 13014-13020.	1.6	2
232	Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses. Cell Discovery, 2021, 7, 21.	3.1	20
236	Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective. Biomedicine, 2021, 9, 412.	1.4	22
237	Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes. Virology Journal, 2021, 18, 87.	1.4	27
238	Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern. Microorganisms, 2021, 9, 926.	1.6	48
239	D936Y and Other Mutations in the Fusion Core of the SARS-CoV-2 Spike Protein Heptad Repeat 1: Frequency, Geographical Distribution, and Structural Effect. Molecules, 2021, 26, 2622.	1.7	21
240	New framework for recombination and adaptive evolution analysis with application to the novel coronavirus SARS-CoV-2. Briefings in Bioinformatics, 2021, 22, .	3.2	7
241	Unraveling the stability landscape of mutations in the SARS-CoV-2 receptor-binding domain. Scientific Reports, 2021, 11, 9166.	1.6	13
242	Deciphering the introduction and transmission of SARS-CoV-2 in the Colombian Amazon Basin. PLoS Neglected Tropical Diseases, 2021, 15, e0009327.	1.3	6
245	Substantial impact of post-vaccination contacts on cumulative infections during viral epidemics. F1000Research, 2021, 10, 315.	0.8	7
249	Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19. Frontiers in Molecular Biosciences, 2021, 8, 635337.	1.6	22

#	ARTICLE	IF	CITATIONS
250	Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study. <i>EBioMedicine</i> , 2021, 66, 103319.	2.7	21
252	Antibodies and Vaccines Target RBD of SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671633.	1.6	108
253	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , 2021, 184, 2332-2347.e16.	13.5	784
254	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. <i>Cell Host and Microbe</i> , 2021, 29, 529-539.e3.	5.1	324
255	COVID-19 and the human innate immune system. <i>Cell</i> , 2021, 184, 1671-1692.	13.5	524
259	Can proteomics-based approaches further help COVID-19 prevention and therapy?. <i>Expert Review of Proteomics</i> , 2021, 18, 241-245.	1.3	5
260	Structural and Functional Characterization of SARS-CoV-2 RBD Domains Produced in Mammalian Cells. <i>Analytical Chemistry</i> , 2021, 93, 6839-6847.	3.2	39
261	CRISPR/Cas System: A Potential Technology for the Prevention and Control of COVID-19 and Emerging Infectious Diseases. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 639108.	1.8	13
262	SARS-CoV-2 variants combining spike mutations and the absence of ORF8 may be more transmissible and require close monitoring. <i>Biochemical and Biophysical Research Communications</i> , 2021, 550, 8-14.	1.0	31
263	Analysis of Key Factors of a SARS-CoV-2 Vaccination Program: A Mathematical Modeling Approach. <i>Epidemiologia</i> , 2021, 2, 140-161.	1.1	22
264	Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. <i>Microbial Cell Factories</i> , 2021, 20, 88.	1.9	37
265	Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants. <i>Journal of Virological Methods</i> , 2021, 290, 114084.	1.0	1
267	Structural impact on SARS-CoV-2 spike protein by D614G substitution. <i>Science</i> , 2021, 372, 525-530.	6.0	344
269	Short Communication:Evidence of Novel SARS-CoV-2 Variants Circulation in Romania. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 329-332.	0.5	8
270	SARS-CoV-2 one year on: evidence for ongoing viral adaptation. <i>Journal of General Virology</i> , 2021, 102, .	1.3	137
272	Killed whole-genome reduced-bacteria surface-expressed coronavirus fusion peptide vaccines protect against disease in a porcine model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	24
274	Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 12904-12910.	7.2	49
275	Implementing Personalized Medicine in COVID-19 in Andalusia: An Opportunity to Transform the Healthcare System. <i>Journal of Personalized Medicine</i> , 2021, 11, 475.	1.1	20

#	ARTICLE	IF	CITATIONS
276	Scrutinizing Coronaviruses Using Publicly Available Bioinformatic Tools: The Viral Structural Proteins as a Case Study. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671923.	1.6	0
277	In Vitro Diagnostics for COVID-19: State-of-the-Art, Future Directions and Role in Pandemic Response. , 0, , .		0
281	Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. <i>Journal of Virology</i> , 2021, 95, .	1.5	80
282	Catching a resurgence: Increase in SARS-CoV-2 viral RNA identified in wastewater 48Âh before COVID-19 clinical tests and 96Âh before hospitalizations. <i>Science of the Total Environment</i> , 2021, 770, 145319.	3.9	159
283	IgV somatic mutation of human antiâ€SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity. <i>JCI Insight</i> , 2021, 6, .	2.3	13
284	SARS-CoV-2 variants of concern are emerging in India. <i>Nature Medicine</i> , 2021, 27, 1131-1133.	15.2	310
285	High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies. <i>Cell</i> , 2021, 184, 2927-2938.e11.	13.5	35
286	Developing a Paper-Based Antigen Assay to Differentiate between Coronaviruses and SARS-CoV-2 Spike Variants. <i>Analytical Chemistry</i> , 2021, 93, 7825-7832.	3.2	26
288	Antigenic Evolution on a Global Scale Reveals the Potential Natural Selection of Severe Acute Respiratory Syndrome-Coronavirus 2 by Pre-existing Cross-Reactive T-Cell Immunity. <i>Frontiers in Microbiology</i> , 2021, 12, 599562.	1.5	5
289	Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab268.	0.4	3
290	Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model. <i>Frontiers in Immunology</i> , 2021, 12, 641447.	2.2	20
293	Molecular Analysis of SARS-CoV-2 Circulating in Bangladesh during 2020 Revealed Lineage Diversity and Potential Mutations. <i>Microorganisms</i> , 2021, 9, 1035.	1.6	7
296	Cellular tropism and antigenicity of mink-derived SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 196.	7.1	7
297	Phytochemical Moieties From Indian Traditional Medicine for Targeting Dual Hotspots on SARS-CoV-2 Spike Protein: An Integrative in-silico Approach. <i>Frontiers in Medicine</i> , 2021, 8, 672629.	1.2	34
298	Graphene Oxide Nanosheets Interact and Interfere with SARSâ€CoVâ€2 Surface Proteins and Cell Receptors to Inhibit Infectivity. <i>Small</i> , 2021, 17, e2101483.	5.2	46
299	Immune profiling of COVID-19: preliminary findings and implications for the pandemic. , 2021, 9, e002550.		15
300	Induction of Humoral and Cellular Immunity by Intradermal Delivery of SARS-CoV-2 Nucleocapsid Protein Using Dissolvable Microneedles. <i>Journal of Immunology Research</i> , 2021, 2021, 1-8.	0.9	9
303	Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2. <i>Viruses</i> , 2021, 13, 927.	1.5	29

#	ARTICLE	IF	CITATIONS
304	Genomic epidemiology of SARS-CoV-2 in Esteio, Rio Grande do Sul, Brazil. <i>BMC Genomics</i> , 2021, 22, 371.	1.2	22
305	Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population. <i>International Reviews of Immunology</i> , 2021, , 1-16.	1.5	6
306	Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates. <i>Science Advances</i> , 2021, 7, .	4.7	28
307	Evolution of SARS CoV-2 Coronavirus Surface Protein Investigated with Mass Spectrometry Based Phylogenetics. <i>Analytical Letters</i> , 0, , 1-13.	1.0	6
309	Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	69
310	Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay. <i>Frontiers in Immunology</i> , 2021, 12, 688436.	2.2	26
313	Phylogenetic Analysis of the 2020 West Nile Virus (WNV) Outbreak in Andalusia (Spain). <i>Viruses</i> , 2021, 13, 836.	1.5	13
316	Comparison of Immunological Profiles of SARS-CoV-2 Variants in the COVID-19 Pandemic Trends: An Immunoinformatics Approach. <i>Antibiotics</i> , 2021, 10, 535.	1.5	11
317	Extensive genetic diversity with novel mutations in spike glycoprotein of severe acute respiratory syndrome coronavirus 2, Bangladesh in late 2020. <i>New Microbes and New Infections</i> , 2021, 41, 100889.	0.8	10
318	Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation. <i>Biochemical and Biophysical Research Communications</i> , 2021, 555, 147-153.	1.0	22
319	Mutations in SARS-CoV-2; Consequences in structure, function, and pathogenicity of the virus. <i>Microbial Pathogenesis</i> , 2021, 154, 104831.	1.3	92
320	Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. <i>Nature Communications</i> , 2021, 12, 3061.	5.8	149
321	Platforms for Personalized Polytherapeutics Discovery in COVID-19. <i>Journal of Molecular Biology</i> , 2021, 433, 166945.	2.0	4
327	Importation, circulation, and emergence of variants of SARS-CoV-2 in the South Indian state of Karnataka. <i>Wellcome Open Research</i> , 2021, 6, 110.	0.9	14
328	Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. <i>Cell Reports</i> , 2021, 35, 109109.	2.9	21
329	Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11. <i>Science Advances</i> , 2021, 7, .	4.7	42
330	Clinical Efficacy of an Osmotic, Antiviral and Anti-Inflammatory Polymeric Nasal Film to Treat Covid-19 Early-Phase Respiratory Symptoms. <i>Open Access Journal of Clinical Trials</i> , 0, Volume 13, 11-20.	1.5	1
331	Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center. <i>Clinical Infectious Diseases</i> , 2022, 74, 821-828.	2.9	47

#	ARTICLE	IF	CITATIONS
332	Origin, evolution and global spread of SARS-CoV-2. <i>Comptes Rendus - Biologies</i> , 2021, 344, 57-75.	0.1	16
333	N-Glycosylation Network Construction and Analysis to Modify Glycans on the Spike (S) Glycoprotein of SARS-CoV-2. <i>Frontiers in Bioinformatics</i> , 2021, 1, .	1.0	5
335	Effect of Genomic and Amino Acid Sequence Mutation on Virulence and Therapeutic Target of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS COV-2). <i>Infection and Drug Resistance</i> , 2021, Volume 14, 2187-2192.	1.1	8
336	Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. <i>Molecules and Cells</i> , 2021, 44, 392-400.	1.0	22
337	Relevant SARS-CoV-2 Genome Variation through Six Months of Worldwide Monitoring. <i>BioMed Research International</i> , 2021, 2021, 1-10.	0.9	6
338	Geographic Differences on Clinical Manifestations of COVID-19 Infection Between Overseas Chinese and Local Chinese Patients. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 2269-2277.	1.1	0
339	Molecular biology of the SARS-CoV-2 spike protein: A review of current knowledge. <i>Journal of Medical Virology</i> , 2021, 93, 5729-5741.	2.5	37
340	Rapid Increase of SARS-CoV-2 Variant B.1.1.7 Detected in Sewage Samples from England between October 2020 and January 2021. <i>MSystems</i> , 2021, 6, e0035321.	1.7	46
341	Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. <i>Nature Communications</i> , 2021, 12, 3815.	5.8	44
342	A SARS-CoV-2 Variant with L452R and E484Q Neutralization Resistance Mutations. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0074121.	1.8	38
343	Glyconanomaterials for Human Virus Detection and Inhibition. <i>Nanomaterials</i> , 2021, 11, 1684.	1.9	5
345	Molecular basis of cross-species ACE2 interactions with SARS-CoV-2-like viruses of pangolin origin. <i>EMBO Journal</i> , 2021, 40, e107786.	3.5	46
346	Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. <i>Nature Communications</i> , 2021, 12, 3661.	5.8	48
347	Ramping Up Antimicrobial Peptides Against Severe Acute Respiratory Syndrome Coronavirus-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 620806.	1.6	28
348	In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms. <i>Frontiers in Microbiology</i> , 2021, 12, 698944.	1.5	40
350	SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence. <i>Journal of Clinical Medicine</i> , 2021, 10, 2635.	1.0	36
351	Predicting the development trend of the second wave of COVID-19 in five European countries. <i>Journal of Medical Virology</i> , 2021, 93, 5896-5907.	2.5	2
352	A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro. <i>Viruses</i> , 2021, 13, 1055.	1.5	4

#	ARTICLE	IF	CITATIONS
353	Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 for viral entry. <i>Molecular Therapy</i> , 2021, 29, 1984-2000.	3.7	19
354	2D MXenes with antiviral and immunomodulatory properties: A pilot study against SARS-CoV-2. <i>Nano Today</i> , 2021, 38, 101136.	6.2	63
355	SARS-CoV-2 variants, spike mutations and immune escape. <i>Nature Reviews Microbiology</i> , 2021, 19, 409-424.	13.6	2,650
356	Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda. <i>Nature Microbiology</i> , 2021, 6, 1094-1101.	5.9	82
357	This is not a pipe – But how harmful is electronic cigarette smoke. <i>Biomedical Journal</i> , 2021, 44, 227-234.	1.4	0
358	Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2021, 12, 676314.	1.5	17
359	V483A: an emerging mutation hotspot of SARS-CoV-2. <i>Future Virology</i> , 2021, 16, 419-429.	0.9	9
361	Notable and Emerging Variants of SARS-CoV-2 Virus: A Quick Glance. <i>Indian Journal of Clinical Biochemistry</i> , 2021, 36, 451-458.	0.9	9
362	N-Glycosylation of the SARS-CoV-2 Receptor Binding Domain Is Important for Functional Expression in Plants. <i>Frontiers in Plant Science</i> , 2021, 12, 689104.	1.7	34
364	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <i>Immunity</i> , 2021, 54, 1276-1289.e6.	6.6	112
365	SARS-CoV-2 Variants in Lebanon: Evolution and Current Situation. <i>Biology</i> , 2021, 10, 531.	1.3	13
366	SARS-CoV-2 Genetic Variability and Non-Specific Immunity Associated with the Use of Different BCG Strains – A Molecular and Clinical Approach. <i>Vaccines</i> , 2021, 9, 639.	2.1	3
367	Comparative genomic analysis demonstrates that true reinfection following SARS-CoV-2 infection is possible. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100015.	0.4	0
368	Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes. <i>Vaccines</i> , 2021, 9, 702.	2.1	5
369	Is SARS-CoV-2 Spike glycoprotein impairing macrophage function via $\alpha 7$ -nicotinic acetylcholine receptors?. <i>Food and Chemical Toxicology</i> , 2021, 152, 112184.	1.8	10
370	A Novel SARS-CoV-2 Viral Sequence Bioinformatic Pipeline Has Found Genetic Evidence That the Viral 3' UTR Is Evolving and Generating Increased Viral Diversity. <i>Frontiers in Microbiology</i> , 2021, 12, 665041.	1.5	20
371	Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19. <i>Nature Nanotechnology</i> , 2021, 16, 942-951.	15.6	103
373	Rapid screening for SARS-CoV-2 variants of concern in clinical and environmental samples using nested RT-PCR assays targeting key mutations of the spike protein. <i>Water Research</i> , 2021, 197, 117104.	5.3	92

#	ARTICLE	IF	CITATIONS
374	SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2. <i>Immunity</i> , 2021, 54, 1304-1319.e9.	6.6	115
375	Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 754-764.	1.8	5
376	Comparative analysis of mutational hotspots in the spike protein of SARS-CoV-2 isolates from different geographic origins. <i>Gene Reports</i> , 2021, 23, 101100.	0.4	3
378	The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. <i>Frontiers in Immunology</i> , 2021, 12, 687869.	2.2	23
379	Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species. <i>Cell</i> , 2021, 184, 3438-3451.e10.	13.5	100
380	Potential transmission chains of variant B.1.1.7 and co-mutations of SARS-CoV-2. <i>Cell Discovery</i> , 2021, 7, 44.	3.1	16
381	Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveals the Allosteric Duality of Functionally Adaptable Hotspots. <i>Journal of Chemical Theory and Computation</i> , 2021, 17, 4578-4598.	2.3	39
382	An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. <i>Cell</i> , 2021, 184, 3452-3466.e18.	13.5	205
383	Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , 2021, 184, 3086-3108.	13.5	309
385	COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era. <i>Molecular Biotechnology</i> , 2021, 63, 885-897.	1.3	8
386	Wearable materials with embedded synthetic biology sensors for biomolecule detection. <i>Nature Biotechnology</i> , 2021, 39, 1366-1374.	9.4	286
387	Machine Learning Reveals the Critical Interactions for SARS-CoV-2 Spike Protein Binding to ACE2. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 5494-5502.	2.1	44
388	Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 226.	7.1	103
391	Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies. <i>Frontiers in Microbiology</i> , 2021, 12, 698365.	1.5	16
392	Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. <i>Viruses</i> , 2021, 13, 1514.	1.5	12
393	Human immunoglobulin from transchromosomal bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	20
394	New SARS-CoV-2 Variant from Jordan. <i>Microbiology Resource Announcements</i> , 2021, 10, e0053221.	0.3	3
395	ACoRE: Accurate SARS-CoV-2 genome reconstruction for the characterization of intra-host and inter-host viral diversity in clinical samples and for the evaluation of re-infections. <i>Genomics</i> , 2021, 113, 1628-1638.	1.3	8

#	ARTICLE	IF	CITATIONS
396	Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach. <i>Infection, Genetics and Evolution</i> , 2021, 91, 104815.	1.0	8
397	Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7425.	1.8	69
398	SARS-CoV-2 receptor-binding mutations and antibody contact sites. <i>Antibody Therapeutics</i> , 2021, 4, 149-158.	1.2	12
399	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , 2021, 373, 648-654.	6.0	385
400	A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses. <i>Cell and Bioscience</i> , 2021, 11, 128.	2.1	9
401	Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern. <i>JCI Insight</i> , 2021, 6, .	2.3	32
402	Glycosylation of SARS-CoV-2: structural and functional insights. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 7179-7193.	1.9	56
403	Nonlinear Dynamics of the Introduction of a New SARS-CoV-2 Variant with Different Infectiousness. <i>Mathematics</i> , 2021, 9, 1564.	1.1	5
404	An Update on Severe Acute Respiratory Syndrome Coronavirus 2 Diversity in the US National Capital Region: Evolution of Novel and Variants of Concern. <i>Clinical Infectious Diseases</i> , 2022, 74, 1419-1428.	2.9	24
405	Non-permissive SARS-CoV-2 infection in human neurospheres. <i>Stem Cell Research</i> , 2021, 54, 102436.	0.3	19
406	N-terminal domain of SARS CoV-2 spike protein mutation associated reduction in effectivity of neutralizing antibody with vaccinated individuals. <i>Journal of Medical Virology</i> , 2021, 93, 5726-5728.	2.5	19
408	V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity. <i>Journal of Virology</i> , 2021, 95, e0061721.	1.5	90
409	SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. <i>PLoS Medicine</i> , 2021, 18, e1003656.	3.9	109
410	Qualitative analysis of a mathematical model with presymptomatic individuals and two SARS-CoV-2 variants. <i>Computational and Applied Mathematics</i> , 2021, 40, 1.	1.0	14
411	SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. <i>Cell Host and Microbe</i> , 2021, 29, 1124-1136.e11.	5.1	421
412	Comparison and Sensitivity Evaluation of Three Different Commercial Real-Time Quantitative PCR Kits for SARS-CoV-2 Detection. <i>Viruses</i> , 2021, 13, 1321.	1.5	31
413	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 36, 109415.	2.9	206
415	SARS-CoV-2 Mutations and their Viral Variants. <i>Cytokine and Growth Factor Reviews</i> , 2022, 63, 10-22.	3.2	113

#	ARTICLE	IF	CITATIONS
416	SARS-CoV-2 spike glycoprotein-reactive T cells can be readily expanded from COVID-19 vaccinated donors. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1452-1467.	1.3	12
417	L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus. <i>JCI Insight</i> , 2021, 6, .	2.3	31
418	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. <i>Cell Host and Microbe</i> , 2021, 29, 1093-1110.	5.1	73
419	Functionalized Masks: Powerful Materials against COVID-19 and Future Pandemics. <i>Small</i> , 2021, 17, e2102453.	5.2	82
420	A Machine-Generated View of the Role of Blood Glucose Levels in the Severity of COVID-19. <i>Frontiers in Public Health</i> , 2021, 9, 695139.	1.3	32
421	Immune Profile of SARS-CoV-2 Variants of Concern. <i>Frontiers in Digital Health</i> , 2021, 3, 704411.	1.5	3
424	Updated SARS-CoV-2 single nucleotide variants and mortality association. <i>Journal of Medical Virology</i> , 2021, 93, 6525-6534.	2.5	16
425	Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics. <i>Biochemical Pharmacology</i> , 2021, 189, 114424.	2.0	27
428	Concurrent mutations in RNA-dependent RNA polymerase and spike protein emerged as the epidemiologically most successful SARS-CoV-2 variant. <i>Scientific Reports</i> , 2021, 11, 13705.	1.6	45
429	Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1349-1361.	2.5	3
430	Comprehensive O-Glycosylation Analysis of the SARS-CoV-2 Spike Protein with Biomimetic Trp-Arg Materials. <i>Analytical Chemistry</i> , 2021, 93, 10444-10452.	3.2	13
431	Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses. <i>Molecular Biology</i> , 2021, 55, 538-547.	0.4	2
432	Ongoing global and regional adaptive evolution of SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	196
433	SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. <i>Microorganisms</i> , 2021, 9, 1542.	1.6	521
434	The molecular basis for SARS-CoV-2 binding to dog ACE2. <i>Nature Communications</i> , 2021, 12, 4195.	5.8	43
435	A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants. <i>Journal of Clinical Medicine</i> , 2021, 10, 3276.	1.0	18
436	Time scale performance of rapid antigen testing for SARS-CoV-2: Evaluation of 10 rapid antigen assays. <i>Journal of Medical Virology</i> , 2021, 93, 6512-6518.	2.5	16
437	Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants. <i>Virologica Sinica</i> , 2021, 36, 934-947.	1.2	12

#	ARTICLE	IF	CITATIONS
438	Detection of SARS-CoV-2 in Wastewater: Community Variability, Temporal Dynamics, and Genotype Diversity. <i>ACS ES&T Water</i> , 2021, 1, 1816-1825.	2.3	7
439	Tracking the pipeline: immunoinformatics and the COVID-19 vaccine design. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	12
440	SARS-CoV-2 reinfection with a virus harboring mutation in the Spike and the Nucleocapsid proteins in Panama. <i>International Journal of Infectious Diseases</i> , 2021, 108, 588-591.	1.5	15
441	Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants. <i>Cell Discovery</i> , 2021, 7, 53.	3.1	14
443	Free Energy Landscapes from SARS-CoV-2 Spike Glycoprotein Simulations Suggest that RBD Opening Can Be Modulated via Interactions in an Allosteric Pocket. <i>Journal of the American Chemical Society</i> , 2021, 143, 11349-11360.	6.6	54
444	Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase. <i>Biochemical Journal</i> , 2021, 478, 2405-2423.	1.7	46
445	Rise and Fall of SARS-CoV-2 Lineage A.27 in Germany. <i>Viruses</i> , 2021, 13, 1491.	1.5	9
446	Computational assessment of select antiviral phytochemicals as potential SARS-Cov-2 main protease inhibitors: molecular dynamics guided ensemble docking and extended molecular dynamics. <i>In Silico Pharmacology</i> , 2021, 9, 44.	1.8	15
448	Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility. <i>Journal of Molecular Biology</i> , 2021, 433, 167051.	2.0	67
449	Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19). <i>Frontiers in Medicine</i> , 2021, 8, 702066.	1.2	14
450	A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	68
452	Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2. <i>PLoS ONE</i> , 2021, 16, e0254734.	1.1	12
454	Design and proof of concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	35
456	The Rise and Fall of a Local SARS-CoV-2 Variant with the Spike Protein Mutation L452R. <i>Vaccines</i> , 2021, 9, 937.	2.1	12
459	Downregulation of CD45 Signaling in COVID-19 Patients Is Reversed by C24D, a Novel CD45 Targeting Peptide. <i>Frontiers in Medicine</i> , 2021, 8, 675963.	1.2	6
461	Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 715464.	2.2	11
462	A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 5000.	5.8	37
464	Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. , 2022, 230, 107967.		40

#	ARTICLE	IF	CITATIONS
465	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. <i>New England Journal of Medicine</i> , 2021, 385, 585-594.	13.9	2,411
467	An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection. <i>Cell and Bioscience</i> , 2021, 11, 164.	2.1	10
468	Direct detection of SARS-CoV-2 antisense and sense genomic RNA in human saliva by semi-autonomous fluorescence in situ hybridization: A proxy for contagiousness?. <i>PLoS ONE</i> , 2021, 16, e0256378.	1.1	7
469	Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy. <i>Cell Discovery</i> , 2021, 7, 67.	3.1	29
470	Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0092121.	1.8	140
471	Genomic analysis reveals a rapid spread and predominance of lambda (C.37) SARS-CoV-2 lineage in Peru despite circulation of variants of concern. <i>Journal of Medical Virology</i> , 2021, 93, 6845-6849.	2.5	47
472	Substantial impact of post-vaccination contacts on cumulative infections during viral epidemics. <i>F1000Research</i> , 2021, 10, 315.	0.8	9
474	Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein. <i>Vaccine: X</i> , 2021, 8, 100098.	0.9	9
476	Molecular Level Dissection of Critical Spike Mutations in SARS-CoV-2 Variants of Concern (VOCs): A Simplified Review. <i>ChemistrySelect</i> , 2021, 6, 7981-7998.	0.7	18
477	Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review. <i>Vaccines</i> , 2021, 9, 869.	2.1	17
478	Probing the Allosteric Inhibition Mechanism of a Spike Protein Using Molecular Dynamics Simulations and Active Compound Identifications. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2827-2835.	2.9	15
479	Probing the Increased Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 (Indian) Tj ETQq1 1 0,784314 rgBT /Over	0.2	3
480	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. <i>JCI Insight</i> , 2021, 6, .	2.3	33
482	ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 315.	7.1	53
483	One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104869.	1.0	49
484	Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease-19 pandemic. <i>Environmental Microbiology</i> , 2022, 24, 2615-2629.	1.8	23
486	Artemether, Artesunate, Arteannuin B, Echinatin, Licochalcone B and Andrographolide Effectively Inhibit SARS-CoV-2 and Related Viruses In Vitro. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 680127.	1.8	28
487	One-shot identification of SARS-CoV-2 RBD escape mutants using yeast screening. <i>Cell Reports</i> , 2021, 36, 109627.	2.9	35

#	ARTICLE	IF	CITATIONS
488	SARS-CoV-2 Genomic Sequencing Revealed N501Y and L452R Mutants of S/A Lineage in Tianjin Municipality, China. <i>Virologica Sinica</i> , 2021, 36, 1228-1231.	1.2	2
490	N439K Variant in Spike Protein Alter the Infection Efficiency and Antigenicity of SARS-CoV-2 Based on Molecular Dynamics Simulation. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 697035.	1.8	19
491	Evolutionary trajectory of SARS-CoV-2 and emerging variants. <i>Virology Journal</i> , 2021, 18, 166.	1.4	105
493	Evolutionary Tracking of SARS-CoV-2 Genetic Variants Highlights an Intricate Balance of Stabilizing and Destabilizing Mutations. <i>MBio</i> , 2021, 12, e0118821.	1.8	30
494	Modelling conformational state dynamics and its role on infection for SARS-CoV-2 Spike protein variants. <i>PLoS Computational Biology</i> , 2021, 17, e1009286.	1.5	79
495	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. <i>Immunity</i> , 2021, 54, 2385-2398.e10.	6.6	46
497	SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. <i>Viruses</i> , 2021, 13, 1687.	1.5	57
498	Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study. <i>Science Immunology</i> , 2021, 6, .	5.6	20
499	Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals. <i>MSphere</i> , 2021, 6, e0057121.	1.3	2
500	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	7.0	57
501	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1652-1661.	5.7	24
502	Molecular characterization of SARS-CoV-2 from Bangladesh: implications in genetic diversity, possible origin of the virus, and functional significance of the mutations. <i>Heliyon</i> , 2021, 7, e07866.	1.4	14
503	Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8498.	1.8	11
504	The Promise of Mutation Resistant Drugs for SARS-CoV-2 That Interdict in the Folding of the Spike Protein Receptor Binding Domain. <i>Covid</i> , 2021, 1, 288-302.	0.7	3
505	Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2489-2509.	1.8	52
506	MALDI-ToF protein profiling as a potential rapid diagnostic platform for COVID-19. <i>Journal of Mass Spectrometry and Advances in the Clinical Lab</i> , 2021, 21, 31-41.	1.3	20
507	Systematic review of host genetic association with Covidâ€19 prognosis and susceptibility: What have we learned in 2020?. <i>Reviews in Medical Virology</i> , 2022, 32, e2283.	3.9	15
508	Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice. <i>Viruses</i> , 2021, 13, 1595.	1.5	23

#	ARTICLE	IF	CITATIONS
509	Myxobacterial depsipeptide chondramides interrupt SARS-CoV-2 entry by targeting its broad, cell tropic spike protein. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 12209-12220.	2.0	10
510	Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. <i>PLoS Pathogens</i> , 2021, 17, e1009772.	2.1	74
511	IMPACT OF VACCINATION ON COVID INFECTION IN HEALTH CARE WORKERS IN WESTERN ZONE OF INDIAN RAILWAYS. , 2021, , 31-34.		0
512	Identification of lectin receptors for conserved SARS-CoV-2 glycosylation sites. <i>EMBO Journal</i> , 2021, 40, e108375.	3.5	44
513	Novel SARS-CoV-2 variants: the pandemics within the pandemic. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1109-1117.	2.8	290
514	Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants. <i>Cell Research</i> , 2021, 31, 1130-1133.	5.7	34
516	SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response. <i>MBio</i> , 2021, 12, e0233521.	1.8	57
517	SAS: A Platform of Spike Antigenicity for SARS-CoV-2. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 713188.	1.8	1
518	Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines. <i>Vaccines</i> , 2021, 9, 992.	2.1	53
520	S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 343.	7.1	24
521	Repurposing fusion inhibitor peptide against SARS-CoV-2. <i>Journal of Computational Chemistry</i> , 2021, 42, 2283-2293.	1.5	14
523	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. <i>Cell Reports</i> , 2021, 36, 109760.	2.9	80
525	Whole-Genome Sequencing of SARS-CoV-2: Assessment of the Ion Torrent AmpliSeq Panel and Comparison with the Illumina MiSeq ARTIC Protocol. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0064921.	1.8	24
526	Molecular evolutionary characteristics of SARS-CoV-2 emerging in the United States. <i>Journal of Medical Virology</i> , 2022, 94, 310-317.	2.5	59
527	Genome Sequences of the Delta Variant (B.1.617.2) and the Kappa Variant (B.1.617.1) Detected in Morocco. <i>Microbiology Resource Announcements</i> , 2021, 10, e0072721.	0.3	6
528	Protons to Patients: targeting endosomal Na ⁺ /H ⁺ exchangers against COVID-19 and other viral diseases. <i>FEBS Journal</i> , 2021, 288, 5071-5088.	2.2	6
530	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. <i>Nature Microbiology</i> , 2021, 6, 1233-1244.	5.9	237
531	The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants. <i>Current Medicinal Chemistry</i> , 2022, 29, 2673-2690.	1.2	12

#	ARTICLE	IF	CITATIONS
532	Interactions of the Receptor Binding Domain of SARS-CoV-2 Variants with hACE2: Insights from Molecular Docking Analysis and Molecular Dynamic Simulation. <i>Biology</i> , 2021, 10, 880.	1.3	38
533	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
534	Magnesium treatment on methylation changes of transmembrane serine protease 2 (TMPRSS2). <i>Nutrition</i> , 2021, 89, 111340.	1.1	6
535	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	1.4	87
536	Insilico study on the effect of SARS-CoV-2 RBD hotspot mutantsâ€™ interaction with ACE2 to understand the binding affinity and stability. <i>Virology</i> , 2021, 561, 107-116.	1.1	44
538	Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients. <i>Viruses</i> , 2021, 13, 1743.	1.5	15
539	A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels. <i>Scientific Reports</i> , 2021, 11, 18428.	1.6	10
540	Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	16
541	Differential mutation profile of SARS-CoV-2 proteins across deceased and asymptomatic patients. <i>Chemico-Biological Interactions</i> , 2021, 347, 109598.	1.7	13
542	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. <i>Cell Host and Microbe</i> , 2021, 29, 1437-1453.e8.	5.1	53
543	Multiplex Biosensing for Simultaneous Detection of Mutations in SARS-CoV-2. <i>ACS Omega</i> , 2021, 6, 25846-25859.	1.6	21
544	Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2. <i>Viruses</i> , 2021, 13, 1936.	1.5	9
545	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	13.5	131
546	Automatic label-free immunoassay with high sensitivity for rapid detection of SARS-CoV-2 nucleocapsid protein based on chemiluminescent magnetic beads. <i>Sensors and Actuators B: Chemical</i> , 2021, 349, 130739.	4.0	24
547	Case report: change of dominant strain during dual SARS-CoV-2 infection. <i>BMC Infectious Diseases</i> , 2021, 21, 959.	1.3	32
548	Dynamic Interactions of Fully Glycosylated SARS-CoV-2 Spike Protein with Various Antibodies. <i>Journal of Chemical Theory and Computation</i> , 2021, 17, 6559-6569.	2.3	13
549	Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	61
550	Wave-wise comparative genomic study for revealing the complete scenario and dynamic nature of COVID-19 pandemic in Bangladesh. <i>PLoS ONE</i> , 2021, 16, e0258019.	1.1	13

#	ARTICLE	IF	CITATIONS
551	COVID-19's U.S. Temperature Response Profile. <i>Environmental and Resource Economics</i> , 2021, 80, 675-704.	1.5	3
552	Pseudoephedrine and its derivatives antagonize wild and mutated severe acute respiratory syndrome (SARS-CoV-2) viruses through blocking virus invasion and antiinflammatory effect. <i>Phytotherapy Research</i> , 2021, 35, 5847-5860.	2.8	8
554	Mutation hotspots and spatiotemporal distribution of SARS-CoV-2 lineages in Brazil, February 2020-2021. <i>Virus Research</i> , 2021, 304, 198532.	1.1	15
555	Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19. <i>Vaccine</i> , 2021, 39, 6050-6056.	1.7	5
556	Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage. <i>Bioorganic Chemistry</i> , 2021, 115, 105196.	2.0	5
557	The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. <i>Journal of Infection</i> , 2021, 83, e1-e3.	1.7	146
558	dsmCRISPR: Dual synthetic mismatches CRISPR/Cas12a-based detection of SARS-CoV-2 D614G mutation. <i>Virus Research</i> , 2021, 304, 198530.	1.1	23
559	In silico study of some selective phytochemicals against a hypothetical SARS-CoV-2 spike RBD using molecular docking tools. <i>Computers in Biology and Medicine</i> , 2021, 137, 104818.	3.9	23
560	COVID-19, the first pandemic in the post-genomic era. <i>Current Opinion in Virology</i> , 2021, 50, 40-48.	2.6	40
561	The Emergence of the New P.4 Lineage of SARS-CoV-2 With Spike L452R Mutation in Brazil. <i>Frontiers in Public Health</i> , 2021, 9, 745310.	1.3	8
562	COVID flood, can vaccines withstand?. <i>Medicine Updates</i> , 2021, 7, 51-62.	0.0	1
563	GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 112011.	2.5	6
564	SARS-CoV-2 spike protein receptor-binding domain N-glycans facilitate viral internalization in respiratory epithelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 579, 69-75.	1.0	15
565	Evolutionary analysis and lineage designation of SARS-CoV-2 genomes. <i>Science Bulletin</i> , 2021, 66, 2297-2311.	4.3	26
566	SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166264.	1.8	5
567	Rapid, inexpensive methods for exploring SARS CoV-2 D614G mutation. <i>Meta Gene</i> , 2021, 30, 100950.	0.3	3
568	Highly sensitive and ultra-rapid antigen-based detection of SARS-CoV-2 using nanomechanical sensor platform. <i>Biosensors and Bioelectronics</i> , 2022, 195, 113647.	5.3	34
570	Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System. <i>Nephron</i> , 2021, 145, 392-403.	0.9	58

#	ARTICLE	IF	CITATIONS
572	Dynamic Network Modeling of Allosteric Interactions and Communication Pathways in the SARS-CoV-2 Spike Trimer Mutants: Differential Modulation of Conformational Landscapes and Signal Transmission via Cascades of Regulatory Switches. <i>Journal of Physical Chemistry B</i> , 2021, 125, 850-873.	1.2	66
575	Human SARS-CoV-2 spike protein mutations. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021, 89, 569-576.	1.5	150
578	Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2. <i>Zoological Research</i> , 2021, 42, 170-181.	0.9	3
579	Treatment Approach, Pharmacological Agents and Vaccines. , 2021, , 145-162.		0
582	COVID-19 vaccines: Where do we stand?. <i>The EuroBiotech Journal</i> , 2021, 5, 4-7.	0.5	1
583	Intra-host evolution during SARS-CoV-2 prolonged infection. <i>Virus Evolution</i> , 2021, 7, veab078.	2.2	68
584	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. <i>Emerging Microbes and Infections</i> , 2021, 10, 507-535.	3.0	202
586	The emerging SARS-CoV-2 variants of concern. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110243.	1.1	82
587	Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective. <i>Antibody Therapeutics</i> , 2020, 3, 285-299.	1.2	34
588	The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies. <i>Briefings in Bioinformatics</i> , 2021, 22, 742-768.	3.2	29
589	The development of neutralizing antibodies against SARS-CoV-2 and their common features. <i>Journal of Molecular Cell Biology</i> , 2021, 12, 980-986.	1.5	13
637	Design of a companion bioinformatic tool to detect the emergence and geographical distribution of SARS-CoV-2 Spike protein genetic variants. <i>Journal of Translational Medicine</i> , 2020, 18, 494.	1.8	15
638	Molecular-Level Anatomy of SARS-CoV-2 for the Battle against the COVID-19 Pandemic. <i>Bulletin of the Chemical Society of Japan</i> , 2021, 94, 1478-1490.	2.0	24
639	Antibody response to SARS-CoV-2 infection in humans: A systematic review. <i>PLoS ONE</i> , 2020, 15, e0244126.	1.1	269
640	Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection. <i>EMBO Molecular Medicine</i> , 2021, 13, e12828.	3.3	43
641	Blocking Effect of Demethylzeylasteral on the Interaction between Human ACE2 Protein and SARS-CoV-2 RBD Protein Discovered Using SPR Technology. <i>Molecules</i> , 2021, 26, 57.	1.7	27
642	Global Prevalence of Adaptive and Prolonged Infections™ Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. <i>Viruses</i> , 2021, 13, 1974.	1.5	9
643	Structure-Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 5133-5140.	2.5	21

#	ARTICLE	IF	CITATIONS
644	Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. <i>Genome Medicine</i> , 2021, 13, 164.	3.6	42
645	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. <i>European Journal of Cancer</i> , 2022, 160, 261-272.	1.3	7
646	The Rapid Assessment of Aggregated Wastewater Samples for Genomic Surveillance of SARS-CoV-2 on a City-Wide Scale. <i>Pathogens</i> , 2021, 10, 1271.	1.2	15
649	Genomic surveillance of SARS-CoV-2 tracks early interstate transmission of P.1 lineage and diversification within P.2 clade in Brazil. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009835.	1.3	23
650	Role of multiple factors likely contributing to severity-mortality of COVID-19. <i>Infection, Genetics and Evolution</i> , 2021, 96, 105101.	1.0	7
652	Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. <i>Scientific Reports</i> , 2021, 11, 20274.	1.6	33
653	InÂvivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential. <i>Cell Reports</i> , 2021, 37, 109838.	2.9	8
655	Mechanisms of SARS-CoV-2 entry into cells. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 3-20.	16.1	1,532
656	The global epidemic of SARSâ€CoVâ€2 variants and their mutational immune escape. <i>Journal of Medical Virology</i> , 2022, 94, 847-857.	2.5	80
657	Development of surfaceâ€enhanced Raman scattering<sc>â€based</sc> immunoassay platforms using hollow Au nanostars for reliable <sc>SARSâ€CoV</sc>â€2 diagnosis. <i>Bulletin of the Korean Chemical Society</i> , 2021, 42, 1699-1705.	1.0	15
658	Uncovering a conserved vulnerability site in SARSâ€CoVâ€2 by a human antibody. <i>EMBO Molecular Medicine</i> , 2021, 13, e14544.	3.3	17
659	Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. <i>Journal of Virology</i> , 2022, 96, JVI0111021.	1.5	29
660	Endonuclease-based genotyping of the RBM as a method to track the emergence or evolution of SARS-CoV-2 variants. <i>IScience</i> , 2021, 24, 103329.	1.9	0
661	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccineâ€boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	6.0	83
662	Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 720357.	1.8	7
663	Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. <i>Microbiology Spectrum</i> , 2021, 9, e0135221.	1.2	13
665	SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China. <i>Frontiers in Public Health</i> , 2021, 9, 716483.	1.3	2
666	Conformational variability of loops in the <sc>SARSâ€CoV</sc>â€2 spike protein. <i>Proteins: Structure, Function and Bioinformatics</i> , 2022, 90, 691-703.	1.5	1

#	ARTICLE	IF	CITATIONS
667	Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization. <i>Communications Biology</i> , 2021, 4, 1196.	2.0	49
668	Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 6103.	5.8	117
669	Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection. <i>Physiology</i> , 2022, 37, 88-100.	1.6	18
672	Temporal-Geographical Dispersion of SARS-CoV-2 Spike Glycoprotein Variant Lineages and Their Functional Prediction Using in Silico Approach. <i>MBio</i> , 2021, 12, e0268721.	1.8	3
673	Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. <i>Science Advances</i> , 2021, 7, eabj3107.	4.7	23
674	SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 368.	7.1	38
675	Nanodiagnostics to Face SARS-CoV-2 and Future Pandemics: From an Idea to the Market and Beyond. <i>ACS Nano</i> , 2021, 15, 17137-17149.	7.3	32
676	High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 2177.	1.5	21
677	Gold-Nanostar-Chitosan-Mediated Delivery of SARS-CoV-2 DNA Vaccine for Respiratory Mucosal Immunization: Development and Proof-of-Principle. <i>ACS Nano</i> , 2021, 15, 17582-17601.	7.3	55
678	Immunology and controlling of coronaviruses; the current enemy for humanity: A review. <i>International Journal of Biological Macromolecules</i> , 2021, , .	3.6	3
679	Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern. <i>IScience</i> , 2021, 24, 103393.	1.9	17
682	Narrative review of the novel coronavirus SARS-CoV-2: update on genomic characteristics, transmissions and animal model. <i>Journal of Thoracic Disease</i> , 2020, 12, 7454-7466.	0.6	1
683	SARS-CoV-2 mutation hotspots incidence in different geographic regions. <i>Microbial Biosystems Journal</i> , 2020, 5, 1-8.	0.3	3
686	Association of SARS-CoV-2 Clades with Clinical, Inflammatory and Virologic Outcomes: An Observational Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
687	Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections. <i>Frontiers in Immunology</i> , 2021, 12, 742167.	2.2	32
688	Analysis of SARS-COV2 spike protein variants among Iraqi isolates. <i>Gene Reports</i> , 2022, 26, 101420.	0.4	12
689	Self and Nonself Short Constituent Sequences of Amino Acids in the SARS-CoV-2 Proteome for Vaccine Development. <i>Covid</i> , 2021, 1, 555-574.	0.7	4
690	First whole genome analysis of the novel coronavirus (SARS-CoV-2) obtained from COVID-19 patients from five districts in Western Serbia. <i>Epidemiology and Infection</i> , 0, , 1-31.	1.0	5

#	ARTICLE	IF	CITATIONS
691	Platelet extracellular vesicles in COVID-19: Potential markers and makers. <i>Journal of Leukocyte Biology</i> , 2021, 111, 63-74.	1.5	26
692	Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 7967-7989.	2.4	40
693	Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 31-56.	0.7	8
694	Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs. <i>Frontiers in Microbiology</i> , 2021, 12, 758948.	1.5	11
695	Transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2), delta variant, between two fully vaccinated healthcare personnel. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1983-1985.	1.0	1
696	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
697	Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies. <i>Antiviral Research</i> , 2021, 196, 105206.	1.9	1
698	Genomic surveillance reveals the detection of SARS-CoV-2 delta, beta, and gamma VOCs during the third wave in Pakistan. <i>Journal of Medical Virology</i> , 2022, 94, 1115-1129.	2.5	21
699	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 378.	7.1	26
706	Genetic Characteristics and Phylogeny of 969-bp S Gene Sequence of SARS-CoV-2 from Hawai'i Reveals the Worldwide Emerging P681H Mutation. <i>Hawai'i Journal of Health & Social Welfare</i> , 2021, 80, 52-61.	0.2	25
707	Screening strategy of TMPRSS2 inhibitors by FRET-based enzymatic activity for TMPRSS2-based cancer and COVID-19 treatment. <i>American Journal of Cancer Research</i> , 2021, 11, 827-836.	1.4	1
708	Delta variant of COVID-19: A simple explanation. <i>Qatar Medical Journal</i> , 2021, 2021, 49.	0.2	6
709	D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 9035-9045.	1.7	34
710	Exposing structural variations in SARS-CoV-2 evolution. <i>Scientific Reports</i> , 2021, 11, 22042.	1.6	6
711	Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. <i>Emerging Microbes and Infections</i> , 2022, 11, 18-29.	3.0	25
712	Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein. <i>Journal of Virology</i> , 2022, 96, JVI0162621.	1.5	24
713	COVID-19 vaccinations: The unknowns, challenges, and hopes. <i>Journal of Medical Virology</i> , 2022, 94, 1336-1349.	2.5	75
714	A Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions. <i>MBio</i> , 2021, , e0293621.	1.8	1

#	ARTICLE	IF	CITATIONS
715	PD-1 blockade counteracts post-“COVID-19 immune abnormalities and stimulates the anti-“SARS-CoV-2 immune response. <i>JCI Insight</i> , 2021, 6, .	2.3	51
716	Immunological Biomarkers in Blood to Monitor the Course and Therapeutic Outcomes of COVID-19. <i>Therapeutic Drug Monitoring</i> , 2021, Publish Ahead of Print, .	1.0	1
717	Underlying selection for the diversity of spike protein sequences of <scp>SARSâ€CoV</scp>â€2. <i>IUBMB Life</i> , 2022, 74, 213-220.	1.5	4
718	Evolution of the SARS-CoV-2 genome and emergence of variants of concern. <i>Archives of Virology</i> , 2022, 167, 293-305.	0.9	28
719	The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 751778.	2.2	142
720	Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight. <i>Viruses</i> , 2021, 13, 2295.	1.5	13
721	Neurological consequences of COVID-19 and brain related pathogenic mechanisms: A new challenge for neuroscience. <i>Brain, Behavior, & Immunity - Health</i> , 2022, 19, 100399.	1.3	33
722	Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19. <i>Journal of Nanobiotechnology</i> , 2021, 19, 391.	4.2	17
723	Targeted Detection of SARS-CoV-2 Nucleocapsid Sequence Variants by Mass Spectrometric Analysis of Tryptic Peptides. <i>Journal of Proteome Research</i> , 2022, 21, 142-150.	1.8	9
724	The glycosylation in SARS-CoV-2 and its receptor ACE2. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 396.	7.1	111
725	Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period. <i>Journal of Infectious Diseases</i> , 2022, 225, 777-784.	1.9	21
726	Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0012321.	5.7	10
728	Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance. <i>Current Opinion in Pharmacology</i> , 2022, 62, 64-73.	1.7	29
729	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
730	Phylogenomics and population genomics of SARS-CoV-2 in Mexico during the pre-vaccination stage reveals variants of interest B.1.1.28.4 and B.1.1.222 or B.1.1.519 and the nucleocapsid mutation S194L associated with symptoms. <i>Microbial Genomics</i> , 2021, 7, .	1.0	13
731	Implications of testicular ACE2 and the reninâ€angiotensin system for SARS-CoV-2 on testis function. <i>Nature Reviews Urology</i> , 2022, 19, 116-127.	1.9	29
732	Emerging SARSâ€CoVâ€2 variants can potentially break set epidemiological barriers in COVIDâ€19. <i>Journal of Medical Virology</i> , 2022, 94, 1300-1314.	2.5	32
733	CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern. <i>Microbiology Spectrum</i> , 2021, 9, e0101721.	1.2	40

#	ARTICLE	IF	CITATIONS
734	A year living with SARS-CoV-2: an epidemiological overview of viral lineage circulation by whole-genome sequencing in Barcelona city (Catalonia, Spain). <i>Emerging Microbes and Infections</i> , 2022, 11, 172-181.	3.0	17
735	Rapid Assessment of Binding Affinity of SARS-COV-2 Spike Protein to the Human Angiotensin-Converting Enzyme 2 Receptor and to Neutralizing Biomolecules Based on Computer Simulations. <i>Frontiers in Immunology</i> , 2021, 12, 730099.	2.2	15
736	Phylogenetic analysis and spike protein mutations in porcine deltacoronavirus with a new variant introduction in Taiwan. <i>Virus Evolution</i> , 2021, 7, veab096.	2.2	2
737	Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021. <i>Infection, Genetics and Evolution</i> , 2022, 97, 105164.	1.0	9
739	Codon usage, phylogeny and binding energy estimation predict the evolution of SARS-CoV-2. <i>One Health</i> , 2021, 13, 100352.	1.5	2
740	Delta variant of COVID-19: A simple explanation. <i>Qatar Medical Journal</i> , 2021, 2021, 49.	0.2	11
741	A second functional furin site in the SARS-CoV-2 spike protein. <i>Emerging Microbes and Infections</i> , 2022, 11, 182-194.	3.0	19
742	Toward a next-generation diagnostic tool: A review on emerging isothermal nucleic acid amplification techniques for the detection of SARS-CoV-2 and other infectious viruses. <i>Analytica Chimica Acta</i> , 2022, 1209, 339338.	2.6	24
743	Immune variants of SARS-CoV-2 could be a significant challenge for developing a pan genotype-specific vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5145-5147.	1.4	0
744	Rapid Identification of SARS-CoV-2 Variants of Concern Using a Portable <i>peak</i> PCR Platform. <i>Analytical Chemistry</i> , 2021, 93, 16350-16359.	3.2	17
745	Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. <i>ACS Infectious Diseases</i> , 2022, 8, 29-58.	1.8	32
746	Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. <i>PLoS Pathogens</i> , 2021, 17, e1010022.	2.1	139
748	Evolutionary Dynamics of Indels in SARS-CoV-2 Spike Glycoprotein. <i>Evolutionary Bioinformatics</i> , 2021, 17, 117693432110646.	0.6	5
749	Detection of SARS-CoV-2 through pool testing for COVID-19: an integrative review. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2021, 54, e0276.	0.4	4
750	Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection (Russian translation). <i>Juvenis Scientia</i> , 2021, 7, 28-59.	0.1	1
751	Rapid and Parallel Adaptive Mutations in Spike S1 Drive Clade Success in SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
752	Phylogenetic pattern of genetic clusters, paradigm shift on spatio-temporal distribution of clades, and impact of spike glycoprotein mutations of SARS-CoV-2 isolates from India. <i>Journal of Global Infectious Diseases</i> , 2021, 13, 164.	0.2	3
753	SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD. <i>Immune Network</i> , 2021, 21, e39.	1.6	3

#	ARTICLE	IF	CITATIONS
754	In Silico Screening of Potential Phytocompounds from Several Herbs against SARS-CoV-2 Indian Delta Variant B.1.617.2 to Inhibit the Spike Glycoprotein Trimer. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 665.	1.3	8
755	Two-step fitness selection for intra-host variations in SARS-CoV-2. <i>Cell Reports</i> , 2022, 38, 110205.	2.9	38
756	ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2. <i>IScience</i> , 2022, 25, 103670.	1.9	29
757	A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients. <i>Gene</i> , 2022, 813, 146113.	1.0	8
758	From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants. <i>Gene</i> , 2022, 814, 146134.	1.0	97
759	Functional nucleic acids as modular components against SARS-CoV-2: From diagnosis to therapeutics. <i>Biosensors and Bioelectronics</i> , 2022, 201, 113944.	5.3	17
761	N-glycosylation profiles of the SARS-CoV-2 spike D614G mutant and its ancestral protein characterized by advanced mass spectrometry. <i>Scientific Reports</i> , 2021, 11, 23561.	1.6	14
762	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. <i>Cell Research</i> , 2022, 32, 269-287.	5.7	54
763	Review on Drug Regulatory Science Promoting COVID-19 Vaccine Development in China. <i>Engineering</i> , 2022, 10, 127-132.	3.2	6
765	A short plus long-amplicon based sequencing approach improves genomic coverage and variant detection in the SARS-CoV-2 genome. <i>PLoS ONE</i> , 2022, 17, e0261014.	1.1	11
766	SARS-CoV-2 Virology. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 251-265.	1.9	7
770	The "LLQY" motif on SARS-CoV-2 spike protein affects S incorporation into virus particles. <i>Journal of Virology</i> , 2022, , jvi0189721.	1.5	1
771	The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance. <i>Cell Reports</i> , 2022, 38, 110218.	2.9	148
772	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
773	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	2.2	176
774	An encodable multiplex microsphere-phase amplification sensing platform detects SARS-CoV-2 mutations. <i>Biosensors and Bioelectronics</i> , 2022, 203, 114032.	5.3	7
775	Monoclonal Antibodies and their Target Specificity Against SARS-CoV-2 Infections: Perspectives and Challenges. <i>Recent Patents on Biotechnology</i> , 2022, 16, 64-78.	0.4	3
776	Critical Mutations of the SARS-CoV-2 Virus. <i>WSEAS Transactions on Biology and Biomedicine</i> , 2022, 19, 22-30.	0.3	1

#	ARTICLE	IF	CITATIONS
778	Allosteric perspective on the mutability and druggability of the SARS-CoV-2 Spike protein. <i>Structure</i> , 2022, 30, 590-607.e4.	1.6	24
779	A Pre-Vaccination Baseline of SARS-CoV-2 Genetic Surveillance and Diversity in the United States. <i>Viruses</i> , 2022, 14, 104.	1.5	1
781	Emergence of a novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India. <i>Journal of Infection and Public Health</i> , 2022, 15, 42-50.	1.9	3
783	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
784	SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection. <i>PLoS Pathogens</i> , 2022, 18, e1010242.	2.1	7
785	Digital Microfluidic qPCR Cartridge for SARS-CoV-2 Detection. <i>Micromachines</i> , 2022, 13, 196.	1.4	16
786	Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction. <i>BMC Molecular and Cell Biology</i> , 2022, 23, 2.	1.0	10
787	Recombinant human interferon- λ 1b inhibits SARS-CoV-2 better than interferon- λ 2b in vitro. <i>Virologica Sinica</i> , 2022, , .	1.2	1
788	Immunity evasion: consequence of the N501Y mutation of the SARS-CoV-2 spike glycoprotein. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 10.	1.5	7
790	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. <i>Journal of Biomedical Science</i> , 2022, 29, 1.	2.6	144
791	The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 18.	7.1	9
792	Interoperability of COVID-19 Clinical Phenotype Data with Host and Viral Genetics Data. <i>BioMed</i> , 2022, 2, 69-81.	0.6	3
794	Evidence of a SARS-CoV-2 double Spike mutation D614G/S939F potentially affecting immune response of infected subjects. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 733-744.	1.9	6
795	Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift. <i>Journal of Medical Virology</i> , 2022, , .	2.5	5
796	Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. <i>Viruses</i> , 2022, 14, 230.	1.5	1
797	Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding. <i>Viruses</i> , 2022, 14, 295.	1.5	12
799	Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry. <i>Angewandte Chemie</i> , 0, , .	1.6	0
801	Variant analysis of SARS-CoV-2 strains with phylogenetic analysis and the Coronavirus Antiviral and Resistance Database. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 157-167.	0.6	2

#	ARTICLE	IF	CITATIONS
802	Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	19
803	HBD-2 binds SARS-CoV-2 RBD and blocks viral entry: Strategy to combat COVID-19. <i>IScience</i> , 2022, 25, 103856.	1.9	23
804	In Planta Production of the Receptor-Binding Domain From SARS-CoV-2 With Human Blood Group A Glycan Structures. <i>Frontiers in Chemistry</i> , 2021, 9, 816544.	1.8	7
805	Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for SARS-CoV-2 Variants after Primary and Booster Immunization. <i>International Journal of Infectious Diseases</i> , 2022, 117, 97-102.	1.5	5
806	Designed SARS-CoV-2 receptor binding domain variants form stable monomers. <i>Biotechnology Journal</i> , 2022, 17, e2100422.	1.8	8
807	Quantifying the effect of government interventions and virus mutations on transmission advantage during COVID-19 pandemic. <i>Journal of Infection and Public Health</i> , 2022, 15, 338-342.	1.9	6
808	SARS-CoV-2 in Egypt: epidemiology, clinical characterization and bioinformatics analysis. <i>Heliyon</i> , 2022, 8, e08864.	1.4	2
809	Highlight of potential impact of new viral genotypes of SARS-CoV-2 on vaccines and anti-viral therapeutics. <i>Gene Reports</i> , 2022, 26, 101537.	0.4	3
810	Early introduction, dispersal and evolution of Delta SARS-CoV-2 in Southern Brazil, late predominance of AY.99.2 and AY.101 related lineages. <i>Virus Research</i> , 2022, 311, 198702.	1.1	15
811	The Influence of New SARS-CoV-2 Variant Omicron (B.1.1.529) on Vaccine Efficacy, its Correlation to Delta Variants: A Computational Approach. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
812	Mutations in human SARS-CoV-2 spike proteins, potential drug binding and epitope sites for COVID-19 therapeutics development. <i>Current Research in Structural Biology</i> , 2022, 4, 41-50.	1.1	25
813	Virus-specific editing identification approach reveals the landscape of A-to-I editing and its impacts on SARS-CoV-2 characteristics and evolution. <i>Nucleic Acids Research</i> , 2022, 50, 2509-2521.	6.5	23
814	Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. <i>Nature Communications</i> , 2022, 13, 688.	5.8	23
818	Persistent SARS-CoV-2 Infection in a Patient With Non-hodgkin Lymphoma: Intra-Host Genomic Diversity Analysis. <i>Frontiers in Virology</i> , 2022, 2, .	0.7	4
819	Genome sequence analysis of SARS-COV-2 isolated from a COVID-19 patient in Erbil, Iraq. <i>Applied Nanoscience (Switzerland)</i> , 2022, , 1-7.	1.6	2
820	Rapid detection of multiple SARS-CoV-2 variants of concern by PAM-targeting mutations. <i>Cell Reports Methods</i> , 2022, 2, 100173.	1.4	12
821	Importation, circulation, and emergence of variants of SARS-CoV-2 in the South Indian state of Karnataka. <i>Wellcome Open Research</i> , 0, 6, 110.	0.9	4
822	Known Cellular and Receptor Interactions of Animal and Human Coronaviruses: A Review. <i>Viruses</i> , 2022, 14, 351.	1.5	11

#	ARTICLE	IF	CITATIONS
823	Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants. <i>Advanced Science</i> , 2022, 9, e2105378.	5.6	12
824	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. <i>Frontiers in Immunology</i> , 2022, 13, 801522.	2.2	73
825	Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak. <i>Cell</i> , 2022, 185, 485-492.e10.	13.5	38
826	Glycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	26
827	An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 44.	7.1	31
829	The variants of SARS-CoV-2 and the challenges of vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 1366-1372.	2.5	29
830	Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa. <i>Journal of Medical Virology</i> , 2022, 94, 1728-1733.	2.5	193
831	COVID-19: comprehensive review on mutations and current vaccines. <i>Archives of Microbiology</i> , 2022, 204, 8.	1.0	26
832	Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. <i>Infection</i> , 2022, 50, 309-325.	2.3	112
833	The emergence, genomic diversity and global spread of SARS-CoV-2. <i>Nature</i> , 2021, 600, 408-418.	13.7	249
834	A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	58
837	Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor. <i>ELife</i> , 2021, 10, .	2.8	29
840	B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies. <i>International Journal of Biological Sciences</i> , 2022, 18, 1844-1851.	2.6	34
841	Insights from computational analysis: how does the SARS-CoV-2 Delta (B.1.617.2) variant hijack ACE2 more effectively?. <i>Physical Chemistry Chemical Physics</i> , 2022, , .	1.3	7
842	Both simulation and sequencing data reveal coinfections with multiple SARS-CoV-2 variants in the COVID-19 pandemic. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1389-1401.	1.9	7
843	Molecular Study for Mutation of N-gene and S-gene COVID-19 Virus. <i>International Journal for Research in Applied Sciences and Biotechnology</i> , 2022, 9, 34-44.	0.2	1
844	Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination. <i>Theranostics</i> , 2022, 12, 2519-2534.	4.6	3
845	Origin of the tight binding mode to ACE2 triggered by multi-point mutations in the omicron variant: a dynamic insight. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 8724-8737.	1.3	11

#	ARTICLE	IF	CITATIONS
846	Tetra-primer ARMS-PCR combined with dual-color fluorescent lateral flow assay for the discrimination of SARS-CoV-2 and its mutations with a handheld wireless reader. <i>Lab on A Chip</i> , 2022, 22, 1531-1541.	3.1	15
848	High diversity in Delta variant across countries revealed by genome-wide analysis of SARS-CoV-2 beyond the Spike protein. <i>Molecular Systems Biology</i> , 2022, 18, e10673.	3.2	18
850	Comparison of Chest Computed Tomography Between the Two Waves of Coronavirus Disease 2019 in Belgium Using Artificial Intelligence. <i>Cureus</i> , 2022, 14, e22203.	0.2	0
851	Phage-Displayed Mimotopes of SARS-CoV-2 Spike Protein Targeted to Authentic and Alternative Cellular Receptors. <i>Viruses</i> , 2022, 14, 384.	1.5	10
852	A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice. <i>Journal of Virology</i> , 2022, 96, JVI0157821.	1.5	14
853	Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant. <i>Frontiers in Microbiology</i> , 2022, 13, 845316.	1.5	8
855	Omicron variant losing its critical mutations in the receptor-binding domain. <i>Journal of Medical Virology</i> , 2022, 94, 2365-2368.	2.5	7
856	Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections. <i>Frontiers in Immunology</i> , 2022, 13, 773652.	2.2	9
857	Strikingly Different Roles of SARS-CoV-2 Fusion Peptides Uncovered by Neutron Scattering. <i>Journal of the American Chemical Society</i> , 2022, 144, 2968-2979.	6.6	30
858	An engineered bispecific human monoclonal antibody against SARS-CoV-2. <i>Nature Immunology</i> , 2022, 23, 423-430.	7.0	38
859	The relevant information about the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the five-question approach (when, where, what, why, and how) and its impact on the environment. <i>Environmental Science and Pollution Research</i> , 2023, 30, 61430-61454.	2.7	6
860	Analyses of Long-Term Epidemic Trends and Evolution Characteristics of Haplotype Subtypes Reveal the Dynamic Selection on SARS-CoV-2. <i>Viruses</i> , 2022, 14, 454.	1.5	2
861	Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes. <i>Medical Review</i> , 2022, 2, 3-22.	0.3	7
862	SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. <i>Frontiers in Medicine</i> , 2022, 9, 815389.	1.2	96
863	Inhibition of Protein N-Glycosylation Blocks SARS-CoV-2 Infection. <i>MBio</i> , 2022, 13, e0371821.	1.8	24
864	SARS-CoV-2 Point Mutation and Deletion Spectra and Their Association with Different Disease Outcomes. <i>Microbiology Spectrum</i> , 2022, 10, e0022122.	1.2	10
866	Tracking the transmission dynamics of COVID-19 with a time-varying coefficient state-space model. <i>Statistics in Medicine</i> , 2022, 41, 2745-2767.	0.8	6
867	SARS-CoV-2 variants and spike mutations involved in second wave of COVID-19 pandemic in India. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	1.3	7

#	ARTICLE	IF	CITATIONS
868	EvoRator: Prediction of Residue-level Evolutionary Rates from Protein Structures Using Machine Learning. <i>Journal of Molecular Biology</i> , 2022, 434, 167538.	2.0	4
870	Profiling of the most reliable mutations from sequenced SARS-CoV-2 genomes scattered in Uzbekistan. <i>PLoS ONE</i> , 2022, 17, e0266417.	1.1	7
871	Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization. <i>Frontiers in Immunology</i> , 2022, 13, 836232.	2.2	15
872	The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. <i>Emerging Microbes and Infections</i> , 2022, 11, 793-803.	3.0	14
873	Engineering Strategies to Overcome the Stability–Function Trade-Off in Proteins. <i>ACS Synthetic Biology</i> , 2022, 11, 1030-1039.	1.9	15
874	Clinico-Genomic Analysis Reiterates Mild Symptoms Post-vaccination Breakthrough: Should We Focus on Low-Frequency Mutations?. <i>Frontiers in Microbiology</i> , 2022, 13, 763169.	1.5	3
875	Comprehensive compartmental model and calibration algorithm for the study of clinical implications of the population-level spread of COVID-19: a study protocol. <i>BMJ Open</i> , 2022, 12, e052681.	0.8	3
877	CovDif, a Tool to Visualize the Conservation between SARS-CoV-2 Genomes and Variants. <i>Viruses</i> , 2022, 14, 561.	1.5	1
878	Impact of the SARS-CoV-2 Delta Variant on the Psychological States and Health-Related Quality of Life in Patients With Crohn’s Disease. <i>Frontiers in Medicine</i> , 2022, 9, 795889.	1.2	1
879	Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell entry process, and cytokine storm in COVID-19. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 964-986.	1.2	8
880	Role of the Microbiome in the Pathogenesis of COVID-19. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 736397.	1.8	17
881	New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression. <i>Journal of Medical Virology</i> , 2022, 94, 3112-3120.	2.5	12
882	Targeted Sanger sequencing to recover key mutations in SARS-CoV-2 variant genome assemblies produced by next-generation sequencing. <i>Microbial Genomics</i> , 2022, 8, .	1.0	7
883	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
884	Antibody escape and global spread of SARS-CoV-2 lineage A.27. <i>Nature Communications</i> , 2022, 13, 1152.	5.8	20
885	Mutations in the genome of severe acute respiratory syndrome coronavirus 2: implications for COVID-19 severity and progression. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210864.	0.4	5
886	35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope. <i>Cell Host and Microbe</i> , 2022, 30, 887-895.e4.	5.1	20
887	SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments. <i>Therapeutic Delivery</i> , 2022, 13, 187-203.	1.2	8

#	ARTICLE	IF	CITATIONS
889	The Runaway Evolution of SARS-CoV-2 Leading to the Highly Evolved Delta Strain. <i>Molecular Biology and Evolution</i> , 2022, 39, .	3.5	14
890	The evolution of SARS-CoV-2 variants and their clinical and healthcare implications. <i>Revista Cl&#x00ed;nica Espan&#x00f5;la</i> , 2022, , .	0.3	1
891	Association of viral load with age, gender, disease severity, and death in severe acute respiratory syndrome coronavirus 2 variants. <i>Journal of Medical Virology</i> , 2022, 94, 3063-3069.	2.5	7
892	Tracking SARS-CoV-2 Mutations & Variants Through the COG-UK-Mutation Explorer. <i>Virus Evolution</i> , 2022, 8, veac023.	2.2	19
893	The N1038S Substitution and 1153EQTRPKKSV1162 Deletion of the S2 Subunit of QX-Type Avian Infectious Bronchitis Virus Can Synergistically Enhance Viral Proliferation. <i>Frontiers in Microbiology</i> , 2022, 13, 829218.	1.5	2
894	The inherent flexibility of receptor binding domains in SARS-CoV-2 spike protein. <i>ELife</i> , 2022, 11, .	2.8	40
895	Rapid and parallel adaptive mutations in spike S1 drive clade success in SARS-CoV-2. <i>Cell Host and Microbe</i> , 2022, 30, 545-555.e4.	5.1	59
896	Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. <i>Frontiers in Immunology</i> , 2022, 13, 773982.	2.2	10
897	Injectable Slow-Release Hydrogel Formulation of a Plant Virus-Based COVID-19 Vaccine Candidate. <i>Biomacromolecules</i> , 2022, 23, 1812-1825.	2.6	20
898	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. <i>EBioMedicine</i> , 2022, 77, 103902.	2.7	23
899	Design of SARS-CoV-2 Variant-Specific PCR Assays Considering Regional and Temporal Characteristics. <i>Applied and Environmental Microbiology</i> , 2022, 88, e0228921.	1.4	12
901	Genomic Surveillance of COVID-19 Variants With Language Models and Machine Learning. <i>Frontiers in Genetics</i> , 2022, 13, 858252.	1.1	8
902	Molecular epidemiological features of SARS-CoV-2 in Japan, 2020â€“1. <i>Virus Evolution</i> , 2022, 8, veac034.	2.2	9
903	Mutational scanning of spike RBD protein for enhanced ACE2 affinity emerging Southeast Asia in the late transmission phase. <i>Scientific Reports</i> , 2022, 12, 5896.	1.6	3
904	Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, 1788.	5.8	30
906	A New Wave of COVID-19 in 2021 with Unique Genetic Characters - Present Global Scenario and Beholding Onwards. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	4
907	The basis of mink susceptibility to SARS-CoV-2 infection. <i>Journal of Applied Genetics</i> , 2022, 63, 543-555.	1.0	5
908	Direct comparison of RT-ddPCR and targeted amplicon sequencing for SARS-CoV-2 mutation monitoring in wastewater. <i>Science of the Total Environment</i> , 2022, 833, 155059.	3.9	29

#	ARTICLE	IF	CITATIONS
909	Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models. <i>Science Translational Medicine</i> , 2022, 14, eabm0899.	5.8	68
910	Dynamic Ca ²⁺ sensitivity stimulates the evolved SARS-CoV-2 spike strain-mediated membrane fusion for enhanced entry. <i>Cell Reports</i> , 2022, 39, 110694.	2.9	19
911	MutCov: A pipeline for evaluating the effect of mutations in spike protein on infectivity and antigenicity of SARS-CoV-2. <i>Computers in Biology and Medicine</i> , 2022, 145, 105509.	3.9	2
912	Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity. <i>Emerging Microbes and Infections</i> , 2022, 11, 1024-1036.	3.0	5
913	Evaluation of binding performance of bioactive compounds against main protease and mutant model spike receptor binding domain of SARS-CoV-2: Docking, ADMET properties and molecular dynamics simulation study. <i>Journal of the Indian Chemical Society</i> , 2022, 99, 100417.	1.3	8
914	Simple Formulae, Deep Learning and Elaborate Modelling for the COVID-19 Pandemic. <i>Encyclopedia</i> , 2022, 2, 679-689.	2.4	1
916	Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112802.	2.5	5
917	Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. <i>Microbiological Research</i> , 2022, 258, 126993.	2.5	22
918	Emergence of SARS-CoV-2 Alpha lineage and its correlation with quantitative wastewater-based epidemiology data. <i>Water Research</i> , 2022, 215, 118257.	5.3	17
919	MXene nanosheets as a novel nanomaterial with antimicrobial applications: A literature review. <i>Journal of Molecular Structure</i> , 2022, 1262, 132958.	1.8	9
920	Next Generation Sequence Prediction Intelligent System for SARS-COV-2 Using Deep Learning Neural Network. , 2021, , .		5
921	Estimating the transmission advantage of the D614G mutant strain of SARS-CoV-2, December 2019 to June 2020. <i>Eurosurveillance</i> , 2021, 26, .	3.9	16
923	Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays. <i>Viruses</i> , 2022, 14, 69.	1.5	5
924	Hotspots for mutations in the SARS-CoV-2 spike glycoprotein: a correspondence analysis. <i>Scientific Reports</i> , 2021, 11, 23622.	1.6	9
925	SARS-CoV-2 Variant Screening Using a Virus-Receptor-Based Electrical Biosensor. <i>Nano Letters</i> , 2022, 22, 50-57.	4.5	28
926	SARS-CoV-2 Therapeutic Landscape, Opportunity and Future Threats. <i>The Open Covid Journal</i> , 2021, 1, 205-215.	0.4	0
927	Development of an efficient Sanger sequencing-based assay for detecting SARS-CoV-2 spike mutations. <i>PLoS ONE</i> , 2021, 16, e0260850.	1.1	11
928	Modeling the onset of symptoms of COVID-19: Effects of SARS-CoV-2 variant. <i>PLoS Computational Biology</i> , 2021, 17, e1009629.	1.5	17

#	ARTICLE	IF	CITATIONS
929	Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 763460.	2.2	16
930	COVID-19 pandemisinin ilk yÄ±lÄ±nda Ä¶Ä¶rendiklerimiz. <i>Hitit Medical Journal</i> ; 0, , .	0.4	0
931	Quality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells. <i>MAbs</i> , 2022, 14, 2005507.	2.6	8
932	Mutational landscape of SARS-CoV-2 genome in Turkey and impact of mutations on spike protein structure. <i>PLoS ONE</i> , 2021, 16, e0260438.	1.1	6
934	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
935	Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab626.	0.4	6
936	Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies. <i>Vaccines</i> , 2022, 10, 23.	2.1	37
937	Viral surface geometry shapes influenza and coronavirus spike evolution through antibody pressure. <i>PLoS Computational Biology</i> , 2021, 17, e1009664.	1.5	4
938	Advances in the design and development of SARS-CoV-2 vaccines. <i>Military Medical Research</i> , 2021, 8, 67.	1.9	26
941	State-of-the-art preclinical evaluation of COVID-19 vaccine candidates. <i>Exploration of Immunology</i> , 0, , 440-460.	1.7	0
942	Impact of SARS-CoV-2 Mutations on Global Travel and the Increasing Number of Re-Infections: A Risk-Assessment Perspective. <i>The Open Covid Journal</i> , 2021, 1, 196-204.	0.4	2
943	Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro. <i>EBioMedicine</i> , 2021, 74, 103712.	2.7	37
944	Genetic Drift Versus Climate Region Spreading Dynamics of COVID-19. <i>Frontiers in Genetics</i> , 2021, 12, 663371.	1.1	3
945	SARS-CoV-2 mutations acquired during serial passage in human cell lines are consistent with several of those found in recent natural SARS-CoV-2 variants. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1925-1934.	1.9	16
946	Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis. <i>Scientific Reports</i> , 2022, 12, 6241.	1.6	12
947	Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. <i>Viruses</i> , 2022, 14, 827.	1.5	14
948	The Delta SARS-CoV-2 Variant of Concern Induces Distinct Pathogenic Patterns of Respiratory Disease in K18-hACE2 Transgenic Mice Compared to the Ancestral Strain from Wuhan. <i>MBio</i> , 2022, 13, e0068322.	1.8	17
949	Variant Analysis and Strategic Clustering to Sub-Lineage of Double Mutant Strain B.1.617 of SARS-CoV-2. <i>Covid</i> , 2022, 2, 513-531.	0.7	1

#	ARTICLE	IF	CITATIONS
950	Modeling the evolution of SARS-CoV-2 under non-pharmaceutical interventions and testing. <i>Evolution, Medicine and Public Health</i> , 2022, 10, 179-188.	1.1	7
951	Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccine-Immunized Plasma. <i>Advanced Science</i> , 2022, 9, e2104333.	5.6	8
952	Transient Expression of Glycosylated SARS-CoV-2 Antigens in <i>Nicotiana benthamiana</i> . <i>Plants</i> , 2022, 11, 1093.	1.6	12
953	Preclinical study of a DNA vaccine targeting SARS-CoV-2. <i>Current Research in Translational Medicine</i> , 2022, 70, 103348.	1.2	9
954	SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't. <i>Journal of Neural Transmission</i> , 2022, 129, 1155-1167.	1.4	19
955	Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants. , 2022, 13, 402.		28
956	SARS-CoV-2: Evolution and Emergence of New Viral Variants. <i>Viruses</i> , 2022, 14, 653.	1.5	39
957	Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2. <i>Methods in Molecular Biology</i> , 2022, 2452, 361-378.	0.4	1
958	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
959	Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants. <i>Frontiers in Immunology</i> , 2022, 13, 804945.	2.2	12
960	A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 702.	2.1	18
961	Detection of Major SARS-CoV-2 Variants of Concern in Clinical Samples via CRISPR-Cas12a-Mediated Mutation-Specific Assay. <i>ACS Synthetic Biology</i> , 2022, 11, 1811-1823.	1.9	9
962	Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent. <i>Future Virology</i> , 2022, 17, 403-413.	0.9	6
963	The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. <i>Vaccines</i> , 2022, 10, 712.	2.1	4
964	Identification and Analysis of SARS-CoV-2 Alpha Variants in the Largest Taiwan COVID-19 Outbreak in 2021. <i>Frontiers in Medicine</i> , 2022, 9, 869818.	1.2	10
965	Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 138.	7.1	140
966	Genetic differentiation and diversity of SARS-CoV-2 Omicron variant in its early outbreak. <i>Biosafety and Health</i> , 2022, 4, 171-178.	1.2	11
967	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. <i>Cell</i> , 2022, 185, 2265-2278.e14.	13.5	77

#	ARTICLE	IF	CITATIONS
968	Probing the Immune System Dynamics of the COVID-19 Disease for Vaccine Designing and Drug Repurposing Using Bioinformatics Tools. <i>Immuno</i> , 2022, 2, 344-371.	0.6	2
969	Comprehensive role of SARS-CoV-2 spike glycoprotein in regulating host signaling pathway. <i>Journal of Medical Virology</i> , 2022, 94, 4071-4087.	2.5	5
970	Unique Aggregation of Retroviral Particles Pseudotyped with the Delta Variant SARS-CoV-2 Spike Protein. <i>Viruses</i> , 2022, 14, 1024.	1.5	2
971	Whole genome sequencing of SARS-CoV2 strains circulating in Iran during five waves of pandemic. <i>PLoS ONE</i> , 2022, 17, e0267847.	1.1	20
972	Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. <i>JAMA Network Open</i> , 2022, 5, e2210780.	2.8	27
973	Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patients. <i>Communications Biology</i> , 2022, 5, 409.	2.0	5
974	SARS-CoV-2 variants – Evolution, spike protein, and vaccines. <i>Biomedical Journal</i> , 2022, 45, 573-579.	1.4	26
975	Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts. <i>Microbiology Spectrum</i> , 2022, 10, e0079122.	1.2	19
976	Massively multiplexed affinity characterization of therapeutic antibodies against SARS-CoV-2 variants. <i>Antibody Therapeutics</i> , 2022, 5, 130-137.	1.2	5
977	nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination. <i>Dr Sulaiman Al Habib Medical Journal</i> , 0, , 1.	0.3	0
978	Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern. <i>Virology</i> , 2022, 572, 44-54.	1.1	21
979	SARS-CoV-2 Lineage A.27: New Data from African Countries and Dynamics in the Context of the COVID-19 Pandemic. <i>Viruses</i> , 2022, 14, 1007.	1.5	5
980	Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: Mutational impacts, concerns, and the possible solutions. <i>Annals of Medicine and Surgery</i> , 2022, 78, 103737.	0.5	33
981	Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins. <i>Antiviral Research</i> , 2022, 203, 105332.	1.9	2
982	The Primacy of Moringa (<i>Moringa oleifera</i> Lam.) in Boosting Nutrition Status and Immunity Defence Amidst the COVID-19 Catastrophe: A Perspective. <i>Phyton</i> , 2022, 91, 1831-1858.	0.4	1
983	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
984	Neutralizing antibody activity against SARS-CoV-2 variants in gestational age-matched mother-infant dyads after infection or vaccination. <i>JCI Insight</i> , 2022, 7, .	2.3	13
985	NGS data vectorization, clustering, and finding key codons in SARS-CoV-2 variations. <i>BMC Bioinformatics</i> , 2022, 23, 187.	1.2	2

#	ARTICLE	IF	CITATIONS
986	Evolution of the SARS-CoV-2 pandemic in India. <i>Medical Journal Armed Forces India</i> , 2022, 78, 264-270.	0.3	7
987	Analysis of the evolution, infectivity and antigenicity of circulating rabies virus strains. <i>Emerging Microbes and Infections</i> , 2022, 11, 1474-1487.	3.0	6
988	An Electrostatically-steered Conformational Selection Mechanism Promotes SARS-CoV-2 Spike Protein Variation. <i>Journal of Molecular Biology</i> , 2022, 434, 167637.	2.0	1
989	Bioinformatics for the Origin and Evolution of Viruses. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1368, 53-71.	0.8	2
990	Studying bona fide SARS-CoV-2 biology in a BSL-2 biosafety environment using a split-virus-genome system. <i>Science China Life Sciences</i> , 2022, 65, 1894-1897.	2.3	2
991	High prevalence of an alpha variant lineage with a premature stop codon in ORF7a in Iraq, winter 2020â€“2021. <i>PLoS ONE</i> , 2022, 17, e0267295.	1.1	8
993	Detecting Potentially Adaptive Mutations from the Parallel and Fixed Patterns in SARS-CoV-2 Evolution. <i>Viruses</i> , 2022, 14, 1087.	1.5	4
994	The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Concern. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	43
995	Human interaction targets of SARS-CoV-2 spike protein: A systematic review. <i>European Journal of Inflammation</i> , 2022, 20, 1721727X2210953.	0.2	3
996	Detection of SARS-CoV-2 Delta Variant of Concern AY.57 and Clinical Characteristics of Imported Cases on a Vietnamese Coal Carrier Vessel in East Kalimantan, Indonesia: A Case Report. <i>Jurnal Respirasi</i> , 2022, 8, 99-105.	0.1	0
997	Investigation and Comparison of Specific Antibodiesâ€™ Affinity Interaction with SARS-CoV-2 Wild-Type, B.1.1.7, and B.1.351 Spike Protein by Total Internal Reflection Ellipsometry. <i>Biosensors</i> , 2022, 12, 351.	2.3	14
998	Transmission of SARS-CoV-2 from humans to animals and potential host adaptation. <i>Nature Communications</i> , 2022, 13, .	5.8	67
999	Microbial ecology and evolution is key to pandemics: using the coronavirus model to mitigate future public health challenges. <i>Heliyon</i> , 2022, 8, e09449.	1.4	3
1000	Competent immune responses to SARS-CoV-2 variants in older adults following two doses of mRNA vaccination. <i>Nature Communications</i> , 2022, 13, .	5.8	12
1001	Real-time allelic assays of SARS-CoV-2 variants to enhance sewage surveillance. <i>Water Research</i> , 2022, 220, 118686.	5.3	17
1002	SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. <i>International Reviews of Immunology</i> , 2023, 42, 393-414.	1.5	26
1003	Nanomechanical assay for ultrasensitive and rapid detection of SARS-CoV-2 based on peptide nucleic acid. <i>Nano Research</i> , 2023, 16, 1183-1195.	5.8	6
1004	A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6123.	1.8	9

#	ARTICLE	IF	CITATIONS
1005	Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	24
1006	SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. <i>Small</i> , 2022, 18, .	5.2	11
1008	Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies. <i>Cell Discovery</i> , 2022, 8, .	3.1	40
1009	Mutational analysis of SARS-CoV-2 variants of concern reveals key tradeoffs between receptor affinity and antibody escape. <i>PLoS Computational Biology</i> , 2022, 18, e1010160.	1.5	14
1010	The past, current and future epidemiological dynamic of SARS-CoV-2. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	24
1012	SARS-CoV-2 intra-host evolution during prolonged infection in an immunocompromised patient. <i>International Journal of Infectious Diseases</i> , 2022, 122, 444-448.	1.5	22
1013	Early Oxygen Treatment Measurements Can Predict COVID-19 Mortality: A Preliminary Study. <i>Healthcare (Switzerland)</i> , 2022, 10, 1146.	1.0	0
1014	The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta variants: A computational approach. <i>Microbial Pathogenesis</i> , 2022, 169, 105619.	1.3	4
1015	Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2. <i>Transfusion Medicine Reviews</i> , 2022, 36, 125-132.	0.9	8
1016	Evolution of SARS-CoV-2 in Spain during the First Two Years of the Pandemic: Circulating Variants, Amino Acid Conservation, and Genetic Variability in Structural, Non-Structural, and Accessory Proteins. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6394.	1.8	17
1017	From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1704-1714.	2.5	15
1018	Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines. <i>Med</i> , 2022, , .	2.2	2
1019	A Rapid, Whole Genome Sequencing Assay for Detection and Characterization of Novel Coronavirus (SARS-CoV-2) Clinical Specimens Using Nanopore Sequencing. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	4
1020	Understanding the mutational frequency in SARS-CoV-2 proteome using structural features. <i>Computers in Biology and Medicine</i> , 2022, 147, 105708.	3.9	6
1021	Nanotechnology: New frontiers in anti-HIV therapy. , 2022, , 129-171.		0
1023	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
1024	Identification of SARS-CoV-2 Variants of Concern Using Amplicon Next-Generation Sequencing. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	10
1025	Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	9

#	ARTICLE	IF	CITATIONS
1026	Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 6064-6073.	2.1	14
1027	The Cholesterol-Binding Sequence in Monomeric C-Reactive Protein Binds to the SARS-CoV-2 Spike Receptor-Binding Domain and Blocks Interaction With Angiotensin-Converting Enzyme 2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1029	Raman Fingerprints of the SARS-CoV-2 Delta Variant and Mechanisms of Its Instantaneous Inactivation by Silicon Nitride Bioceramics. <i>ACS Infectious Diseases</i> , 2022, 8, 1563-1581.	1.8	7
1030	A smartphone-based platform for ratiometric visualization of SARS-CoV-2 via an oligonucleotide probe. <i>Mikrochimica Acta</i> , 2022, 189, .	2.5	6
1031	Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody. <i>Viruses</i> , 2022, 14, 1560.	1.5	21
1032	Trimeric receptor-binding domain of SARS-CoV-2 acts as a potent inhibitor of ACE2 receptor-mediated viral entry. <i>IScience</i> , 2022, 25, 104716.	1.9	6
1033	Rapid and Affordable High Throughput Screening of SARS-CoV-2 Variants Using Denaturing High-Performance Liquid Chromatography Analysis. <i>Frontiers in Virology</i> , 0, 2, .	0.7	0
1034	Identification of Surface Glycoprotein Mutations of SARS-CoV-2 in Isolated Strains from Iraq. <i>Medical Immunology (Russia)</i> , 2022, 24, 729-740.	0.1	2
1035	Characterization and Utilization of Disulfide-Bonded SARS-CoV-2 Receptor Binding Domain of Spike Protein Synthesized by Wheat Germ Cell-Free Production System. <i>Viruses</i> , 2022, 14, 1461.	1.5	3
1036	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	6
1038	Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications. <i>Journal of Clinical Immunology</i> , 2022, 42, 1371-1378.	2.0	11
1039	Functional mutations of SARS-CoV-2: implications to viral transmission, pathogenicity and immune escape. <i>Chinese Medical Journal</i> , 0, Publish Ahead of Print, .	0.9	3
1041	A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1042	SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron. <i>Emerging Microbes and Infections</i> , 2022, 11, 1819-1827.	3.0	10
1043	Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1044	Multifaceted Assessment of Wastewater-Based Epidemiology for SARS-CoV-2 in Selected Urban Communities in Davao City, Philippines: A Pilot Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8789.	1.2	5
1045	Insight into Genetic Characteristics of Identified SARS-CoV-2 Variants in Egypt from March 2020 to May 2021. <i>Pathogens</i> , 2022, 11, 834.	1.2	9
1046	Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8177.	1.8	5

#	ARTICLE	IF	CITATIONS
1047	Nanosponges: An overlooked promising strategy to combat SARS-CoV-2. <i>Drug Discovery Today</i> , 2022, 27, 103330.	3.2	6
1048	Perspective Chapter: Bioinformatics Study of the Evolution of SARS-CoV-2 Spike Protein. <i>Infectious Diseases</i> , 0, , .	4.0	0
1049	Dynamics of Viral Infection and Evolution of SARS-CoV-2 Variants in the Calabria Area of Southern Italy. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	10
1050	Sequence Similarity Network Analysis Provides Insight into the Temporal and Geographical Distribution of Mutations in SARS-CoV-2 Spike Protein. <i>Viruses</i> , 2022, 14, 1672.	1.5	0
1051	Recurrent SARS-CoV-2 mutations in immunodeficient patients. <i>Virus Evolution</i> , 2022, 8, .	2.2	53
1052	Immunological and Pathological Peculiarity of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	2
1053	Missense mutations in spike protein of SARS-CoV-2 delta variant contribute to the alteration in viral structure and interaction with hACE2 receptor. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	6
1054	Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies. <i>Communications Biology</i> , 2022, 5, .	2.0	5
1055	SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors. <i>Cell Reports</i> , 2022, 40, 111284.	2.9	4
1056	The Microalgal Diatoxanthin Inflects the Cytokine Storm in SARS-CoV-2 Stimulated ACE2 Overexpressing Lung Cells. <i>Antioxidants</i> , 2022, 11, 1515.	2.2	5
1057	Evolutionary remodelling of N-terminal domain loops fine-tunes SARS-CoV-2 spike. <i>EMBO Reports</i> , 2022, 23, .	2.0	18
1058	Insights into the microevolution of SARS-ACE2 interactions: in silico analysis of glycosylation and SNP pattern. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 6442-6449.	2.0	3
1059	Uninvited Guest: Arrival and Dissemination of Omicron Lineage SARS-CoV-2 in St. Petersburg, Russia. <i>Microorganisms</i> , 2022, 10, 1676.	1.6	5
1061	Emergence and Spread of the SARS-CoV-2 Variant of Concern Delta across Different Brazilian Regions. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	9
1062	Reconsidering the need for gain-of-function research on enhanced potential pandemic pathogens in the post-COVID-19 era. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	2
1063	The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	11
1064	Multi-task learning for predicting SARS-CoV-2 antibody escape. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
1065	Prediction of infectivity of SARS-CoV-2 virus based on Spike-hACE-2 interaction. <i>VirusDisease</i> , 0, , .	1.0	0

#	ARTICLE	IF	CITATIONS
1066	The Experience of COVID-19: Variants, Vaccines and Policies. , 0, 8, 230-235.		0
1067	Core fucose-specific <i>Pholiota squarrosa</i> lectin (PhoSL) as a potent broad-spectrum inhibitor of SARS-CoV-2 infection. FEBS Journal, 2023, 290, 412-427.	2.2	4
1068	Considering epitopes conservity in targeting SARS-CoV-2 mutations in variants: a novel immunoinformatics approach to vaccine design. Scientific Reports, 2022, 12, .	1.6	6
1069	Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine. EBioMedicine, 2022, 83, 104196.	2.7	26
1070	Sequencing and mutations analysis of the first recorded SARS-CoV-2 Omicron variant during the fourth wave of pandemic in Iraq. Brazilian Journal of Infectious Diseases, 2022, 26, 102677.	0.3	2
1071	Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. IScience, 2022, 25, 104886.	1.9	5
1072	Selective reversed-phase high-performance liquid chromatography method for the determination of intact SARS-CoV-2 spike protein. Journal of Chromatography A, 2022, 1680, 463424.	1.8	2
1073	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. Biomedicine and Pharmacotherapy, 2022, 154, 113522.	2.5	56
1075	Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	7
1076	Systematic analysis and comparison of O-glycosylation of five recombinant spike proteins in β 2-coronaviruses. Analytica Chimica Acta, 2022, 1230, 340394.	2.6	2
1077	Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening. Virus Research, 2022, 321, 198915.	1.1	2
1078	Nanozyme-strip for rapid and ultrasensitive nucleic acid detection of SARS-CoV-2. Biosensors and Bioelectronics, 2022, 217, 114739.	5.3	25
1079	Global Biologic Characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2. , 2022, , 161-181.		0
1080	RBD spatial orientation of the spike protein and its binding to ACE2: insight into the high infectivity of the SARS-CoV-2 Delta variant from MD simulations. Physical Chemistry Chemical Physics, 0, , .	1.3	2
1081	Smart Door System for Maintaining Social Distancing and Controlling Spread of Infectious Disease. Lecture Notes in Electrical Engineering, 2022, , 527-537.	0.3	0
1082	Antibody-mediated immunity to SARS-CoV-2 spike. Advances in Immunology, 2022, , 1-69.	1.1	12
1083	Precision Medicine in Infectious Disease. , 2022, , 221-257.		2
1084	Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	7

#	ARTICLE	IF	CITATIONS
1085	SARS-CoV-2 Genetic Diversity and Lineage Dynamics in Egypt during the First 18 Months of the Pandemic. <i>Viruses</i> , 2022, 14, 1878.	1.5	4
1086	Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2. <i>Journal of Microbiology and Biotechnology</i> , 2022, 32, 1073-1085.	0.9	2
1087	Broad-spectrum antiviral activity of <i>Spatholobus suberectus</i> Dunn against SARS-CoV-2, SARS-CoV-1, H5N1, and other enveloped viruses. <i>Phytotherapy Research</i> , 2022, 36, 3232-3247.	2.8	12
1088	Whole genome sequencing analysis of SARS-CoV-2 from Malaysia: From alpha to Omicron. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
1089	African Swine Fever Vaccinology: The Biological Challenges from Immunological Perspectives. <i>Viruses</i> , 2022, 14, 2021.	1.5	12
1090	Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1091	Retrospective Cohort Study of COVID-19 in Patients of the Brazilian Public Health System with SARS-CoV-2 Omicron Variant Infection. <i>Vaccines</i> , 2022, 10, 1504.	2.1	2
1092	Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation. <i>Vaccine</i> , 2022, , .	1.7	3
1093	Molecular Mechanism of the Non-Covalent Orally Targeted SARS-CoV-2 M ^{pro} Inhibitor S-217622 and Computational Assessment of Its Effectiveness against Mainstream Variants. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 8893-8901.	2.1	7
1094	Evolution of SARS-CoV-2 during the first year of the COVID-19 pandemic in Northwestern Argentina. <i>Virus Research</i> , 2023, 323, 198936.	1.1	5
1095	NanoCoV19: An analytical pipeline for rapid detection of severe acute respiratory syndrome coronavirus 2. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
1096	Pathogenetic Mechanisms Of Dry Eye Syndrome In A Novel Coronavirus Infection Caused By SARS-CoV-2. <i>Russian Open Medical Journal</i> , 2022, 11, .	0.1	0
1097	Quantifying Mutational Response to Track the Evolution of SARS-CoV-2 Spike Variants: Introducing a Statistical-Mechanics-Guided Machine Learning Method. <i>Journal of Physical Chemistry B</i> , 2022, 126, 7895-7905.	1.2	5
1098	Biophysical and Biochemical Characterization of the Receptor Binding Domain of SARS-CoV-2 Variants. <i>Protein Journal</i> , 2022, 41, 457-467.	0.7	0
1099	Molecular modelling on multipeptide-based vaccine against SARS-CoV-2 using immunoinformatics, molecular docking, and molecular dynamics simulation. <i>SAR and QSAR in Environmental Research</i> , 2022, 33, 649-675.	1.0	3
1100	Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity. <i>Gut Microbes</i> , 2022, 14, .	4.3	8
1102	COVID-19 Positive Status is Associated with Increased In-hospital Mortality in Patients with Acute Myocardial Infarction: A Systematic Review and Meta-analysis. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 17-24.	0.4	2
1103	Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy. <i>Microbiology Spectrum</i> , 0, , .	1.2	0

#	ARTICLE	IF	CITATIONS
1104	Novel skewed usage of B-cell receptors in COVID-19 patients with various clinical presentations. <i>Immunology Letters</i> , 2022, 249, 23-32.	1.1	4
1105	Structural heterogeneity and precision of implications drawn from cryo-electron microscopy structures: SARS-CoV-2 spike-protein mutations as a test case. <i>European Biophysics Journal</i> , 2022, 51, 555-568.	1.2	4
1106	Role for <i>N</i> -glycans and calnexin-calreticulin chaperones in SARS-CoV-2 Spike maturation and viral infectivity. <i>Science Advances</i> , 2022, 8, .	4.7	10
1107	Mechanosensing view of SARS-CoV-2 infection by a DNA nano-assembly. <i>Cell Reports Physical Science</i> , 2022, 3, 101048.	2.8	9
1108	SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility. <i>Frontiers in Medical Technology</i> , 0, 4, .	1.3	6
1109	Genomic and structural mechanistic insight to reveal the differential infectivity of omicron and other variants of concern. <i>Computers in Biology and Medicine</i> , 2022, 150, 106129.	3.9	6
1111	SARS-CoV-2 from COVID-19 Patients in the Republic of Moldova: Whole-Genome Sequencing Results. <i>Viruses</i> , 2022, 14, 2310.	1.5	1
1112	Cell Entry and Unusual Replication of SARS-CoV-2. <i>Current Drug Targets</i> , 2022, 23, 1539-1554.	1.0	1
1113	De novo selected hACE2 mimics that integrate hotspot peptides with aptameric scaffolds for binding tolerance of SARS-CoV-2 variants. <i>Science Advances</i> , 2022, 8, .	4.7	9
1114	Atomistic insights into the binding of SARS-CoV-2 spike receptor binding domain with the human ACE2 receptor: The importance of residue 493. <i>Journal of Molecular Graphics and Modelling</i> , 2023, 118, 108360.	1.3	5
1115	Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. <i>Journal of Pharmaceutical Analysis</i> , 2023, 13, 1-10.	2.4	1
1116	Development of SARS-CoV-2 animal vaccines using a stable and efficient NDV expression system. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	2
1117	Dissecting Naturally Arising Amino Acid Substitutions at Position L452 of SARS-CoV-2 Spike. <i>Journal of Virology</i> , 2022, 96, .	1.5	5
1118	Variation analysis of SARS-CoV-2 complete sequences from Iran. <i>Future Virology</i> , 0, , .	0.9	0
1119	A core epitope targeting antibody of SARS-CoV-2. <i>Protein and Cell</i> , 0, , .	4.8	0
1120	Quantum tunnelling in the context of SARS-CoV-2 infection. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
1121	Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1122	SARS-CoV-2 variants of concern and spike protein mutational dynamics in a Swedish cohort during 2021, studied by Nanopore sequencing. <i>Virology Journal</i> , 2022, 19, .	1.4	5

#	ARTICLE	IF	CITATIONS
1123	Synthesis, Processing, and Function of N-Glycans in N-Glycoproteins. <i>Advances in Neurobiology</i> , 2023, , 65-93.	1.3	3
1124	A proteome-scale map of the SARS-CoV-2 human contactome. <i>Nature Biotechnology</i> , 2023, 41, 140-149.	9.4	29
1125	Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
1126	Electrochemical Aptasensing of SARS-CoV-2 Based on Triangular Prism DNA Nanostructures and Dumbbell Hybridization Chain Reaction. <i>Analytical Chemistry</i> , 2022, 94, 14755-14760.	3.2	19
1127	Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12267.	1.8	9
1128	Perspective Chapter: Emerging SARS-CoV-2 Variants of Concern (VOCs) and Their Impact on Transmission Rate, Disease Severity and Breakthrough Infections. <i>Infectious Diseases</i> , 0, , .	4.0	0
1129	Genetic diversity and evolutionary convergence of cryptic SARS- CoV-2 lineages detected via wastewater sequencing. <i>PLoS Pathogens</i> , 2022, 18, e1010636.	2.1	32
1130	Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation. <i>Chemico-Biological Interactions</i> , 2022, 368, 110244.	1.7	4
1131	Derivatization of sialylated glycopeptides plus based sialoglycopeptides enrichment using cation exchange media. <i>Analytica Chimica Acta</i> , 2022, 1233, 340492.	2.6	1
1132	Characterization and Function of Glycans on the Spike Proteins of SARS-CoV-2 Variants of Concern. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	8
1133	One-by-one single-molecule counting method for digital quantification of SARS-CoV-2 RNA. <i>Nano Today</i> , 2022, 47, 101664.	6.2	3
1134	Novel coronavirus mutations: Vaccine development and challenges. <i>Microbial Pathogenesis</i> , 2022, 173, 105828.	1.3	7
1135	Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides. <i>Antiviral Research</i> , 2022, 208, 105445.	1.9	9
1136	Molecular dynamics simulations of the spike trimeric ectodomain of the SARS-CoV-2 Omicron variant: structural relationships with infectivity, evasion to immune system and transmissibility. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 9326-9343.	2.0	4
1137	Efficient Tracing of the SARS-CoV-2 Omicron Variants in Santa Barbara County Using a Rapid Quantitative Reverse Transcription PCR Assay. <i>Diagnostics</i> , 2022, 12, 2805.	1.3	2
1138	Genome characterization, phylogenomic assessment and spatio-temporal dynamics study of highly mutated BA variants from India. <i>Indian Journal of Medical Microbiology</i> , 2022, , .	0.3	1
1139	Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond. <i>IScience</i> , 2022, 25, 105507.	1.9	10
1140	Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach. <i>Molecules</i> , 2022, 27, 7522.	1.7	5

#	ARTICLE	IF	CITATIONS
1141	Structural effects of spike protein D614G mutation in SARS-CoV-2. <i>Biophysical Journal</i> , 2023, 122, 2910-2920.	0.2	11
1142	Longitudinal antibody titer, avidity, and neutralizing responses after SARS-CoV-2 infection. <i>Heliyon</i> , 2022, 8, e11676.	1.4	4
1143	Molecular dynamics study on the strengthening behavior of Delta and Omicron SARS-CoV-2 spike RBD improved receptor-binding affinity. <i>PLoS ONE</i> , 2022, 17, e0277745.	1.1	4
1145	Deep Learning Based NLP Embedding Approach for Biosequence Classification. <i>Lecture Notes in Computer Science</i> , 2022, , 161-173.	1.0	2
1146	Identification of an immunogenic epitope and protective antibody against the furin cleavage site of SARS-CoV-2. <i>EBioMedicine</i> , 2023, 87, 104401.	2.7	0
1147	Aero-manufacture of nanobulges for an in-place anticoronaviral on air filters. <i>Journal of Hazardous Materials</i> , 2023, 445, 130458.	6.5	1
1148	SARS-CoV-2 Omicron Variant Genomic Sequences and Their Epidemiological Correlates Regarding the End of the Pandemic: In Silico Analysis. <i>JMIR Bioinformatics and Biotechnology</i> , 0, 4, e42700.	0.4	2
1150	Structural Profiles of SARS-CoV-2 Variants in India. <i>Current Microbiology</i> , 2023, 80, .	1.0	4
1151	Detection of SARS-CoV-2 and Variants in Hospital Wastewater in a Developing Country. <i>Water (Switzerland)</i> , 2022, 14, 3798.	1.2	3
1152	Pre-processing SARS-CoV-2 Sequence Data for Application of Machine Learning Techniques for Visualization and Clustering of Virus Characteristics. , 2022, , .		0
1153	SARS-CoV-2 Delta Variant: Interplay between Individual Mutations and Their Allosteric Synergy. <i>Biomolecules</i> , 2022, 12, 1742.	1.8	6
1155	Distribution of intra-host variations and mutations in the genomes of SARS-CoV-2 and their implications on detection and therapeutics. <i>MedComm</i> , 2022, 3, .	3.1	2
1156	Inferring selection effects in SARS-CoV-2 with Bayesian Viral Allele Selection. <i>PLoS Genetics</i> , 2022, 18, e1010540.	1.5	8
1157	Rapid Point-of-Care Assay by SERS Detection of SARS-CoV-2 Virus and Its Variants. <i>Analytical Chemistry</i> , 2022, 94, 17795-17802.	3.2	12
1158	Supramolecular filaments for concurrent ACE2 docking and enzymatic activity silencing enable coronavirus capture and infection prevention. <i>Matter</i> , 2023, 6, 583-604.	5.0	6
1159	Genomic analysis of SARS-CoV-2 variants of concern circulating in Hawaii to facilitate public-health policies. <i>PLoS ONE</i> , 2022, 17, e0278287.	1.1	0
1160	The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant. <i>IScience</i> , 2022, 25, 105720.	1.9	27
1161	The SARS-CoV-2 Delta (B.1.617.2) variant with Spike N501Y mutation in the shadow of Omicron emergence. <i>Heliyon</i> , 2022, , e12650.	1.4	0

#	ARTICLE	IF	CITATIONS
1162	Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
1163	Containment of SARS-CoV-2 Delta strain in Guangzhou, China by quarantine and social distancing: a modelling study. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1164	Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
1165	Cross-reaction of current available SARS-CoV-2 MAbs against the pangolin-origin coronavirus GX/P2V/2017. <i>Cell Reports</i> , 2022, 41, 111831.	2.9	2
1166	Mutations in SARS-CoV-2 structural proteins: a global analysis. <i>Virology Journal</i> , 2022, 19, .	1.4	30
1167	Retrospective in silico mutation profiling of SARS-CoV-2 structural proteins circulating in Uganda by July 2021: Towards refinement of COVID-19 disease vaccines, diagnostics, and therapeutics. <i>PLoS ONE</i> , 2022, 17, e0279428.	1.1	0
1168	Mixed formulation of mRNA and proteinâ€based COVIDâ€19 vaccines triggered superior neutralizing antibody responses. <i>MedComm</i> , 2022, 3, .	3.1	1
1169	Genomic Tracking of SARS-CoV-2 Variants in Myanmar. <i>Vaccines</i> , 2023, 11, 6.	2.1	0
1171	Attenuation and Degeneration of SARS-CoV-2 Despite Adaptive Evolution. <i>Cureus</i> , 2023, , .	0.2	0
1172	Mutational analysis of the spike protein of SARS-COV-2 isolates revealed atomistic features responsible for higher binding and infectivity. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
1173	A strategy for evaluating potential antiviral resistance to small molecule drugs and application to SARS-CoV-2. <i>Scientific Reports</i> , 2023, 13, .	1.6	6
1174	Characterization and phylogenetic analysis of Iranian SARSâ€CoVâ€2 genomes: A phylogenomic study. <i>Health Science Reports</i> , 2023, 6, .	0.6	1
1175	In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations. <i>Bioengineering</i> , 2023, 10, 100.	1.6	10
1176	Structural proteins of SARS-CoV-2. <i>Medical Herald of the South of Russia</i> , 2023, 13, 45-52.	0.2	0
1177	Severe Acute Respiratory Syndrome Coronavirus-2 Delta Variant Study In Vitro and Vivo. <i>Current Issues in Molecular Biology</i> , 2023, 45, 249-267.	1.0	0
1178	Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection. <i>Cell Reports</i> , 2023, 42, 112075.	2.9	5
1180	A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy. <i>PLoS Pathogens</i> , 2023, 19, e1011085.	2.1	5
1182	Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection. , 2023, , 237-262.		0

#	ARTICLE	IF	CITATIONS
1184	Reverse transcription-loop-mediated isothermal amplification (RT-LAMP) assay as a rapid molecular diagnostic tool for COVID-19 in healthcare workers. <i>Journal of Clinical Virology Plus</i> , 2023, 3, 100134.	0.4	3
1186	Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals. <i>ISME Journal</i> , 2023, 17, 549-560.	4.4	5
1187	Unconventional secretion of unglycosylated ORF8 is critical for the cytokine storm during SARS-CoV-2 infection. <i>PLoS Pathogens</i> , 2023, 19, e1011128.	2.1	11
1188	Modeling the spread dynamics of multiple-variant coronavirus disease under public health interventions: A general framework. <i>Information Sciences</i> , 2023, 628, 469-487.	4.0	4
1189	State of the art in epitope mapping and opportunities in COVID-19. <i>Future Science OA</i> , 2023, 9, .	0.9	4
1190	A bat MERS-like coronavirus circulates in pangolins and utilizes human DPP4 and host proteases for cell entry. <i>Cell</i> , 2023, 186, 850-863.e16.	13.5	23
1192	Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy. <i>Vaccines</i> , 2023, 11, 806.	2.1	1
1193	Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1194	The SpACE-CCM: A facile and versatile cell culture medium-based biosensor for detection of SARS-CoV-2 spike-ACE2 interaction. <i>Biosensors and Bioelectronics</i> , 2023, 227, 115169.	5.3	0
1195	Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. <i>Heliyon</i> , 2023, 9, e13285.	1.4	4
1197	A Protein Co-Conservation Network Model Characterizes Mutation Effects on SARS-CoV-2 Spike Protein. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3255.	1.8	4
1198	Computational Analysis Predicts Correlations among Amino Acids in SARS-CoV-2 Proteomes. <i>Biomedicines</i> , 2023, 11, 512.	1.4	0
1199	Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1200	Employing T-Cell Memory to Effectively Target SARS-CoV-2. <i>Pathogens</i> , 2023, 12, 301.	1.2	0
1201	Mathematical Modeling of SARS-CoV-2 Omicron Wave under Vaccination Effects. <i>Computation</i> , 2023, 11, 36.	1.0	9
1202	Optimized workplace risk mitigation measures for SARS-CoV-2 in 2022. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
1203	Immunoinformatics Study of SARS-CoV-2 Nucleocapsid Phosphoprotein Identifies Promising Epitopes with Mutational Implications. <i>Moscow University Biological Sciences Bulletin</i> , 2022, 77, 251-257.	0.1	2
1204	Nigelladine A among Selected Compounds from <i>Nigella sativa</i> Exhibits Propitious Interaction with Omicron Variant of SARS-CoV-2: An In Silico Study. <i>International Journal of Clinical Practice</i> , 2023, 2023, 1-14.	0.8	2

#	ARTICLE	IF	CITATIONS
1206	Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
1207	In silico prediction of potential inhibitors for SARS-CoV-2 Omicron variant using molecular docking and dynamics simulation-based drug repurposing. <i>Journal of Molecular Modeling</i> , 2023, 29, .	0.8	2
1208	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4401.	1.8	4
1209	Epidemiological features, genomic characteristics, and origin tracing of the COVID-19 outbreaks in Beijing from January to September 2022. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	0
1210	Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. <i>Vaccines</i> , 2023, 11, 545.	2.1	3
1211	Nasal sprays for treating COVID-19: a scientific note. <i>Pharmacological Reports</i> , 2023, 75, 249-265.	1.5	10
1212	Rapid Shift from SARS-CoV-2 Delta to Omicron Sub-Variants within a Dynamic Southern U.S. Borderplex. <i>Viruses</i> , 2023, 15, 658.	1.5	3
1213	CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern. <i>TrAC - Trends in Analytical Chemistry</i> , 2023, 161, 117000.	5.8	11
1214	Effectiveness of mRNA and viral vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
1215	Mutational analysis of catalytic site domain of CCHFV L RNA segment. <i>Journal of Molecular Modeling</i> , 2023, 29, .	0.8	1
1216	A Rapid Method for Generating Infectious SARS-CoV-2 and Variants Using Mutagenesis and Circular Polymerase Extension Cloning. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	5
1217	Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1218	ZnO-Based Electrochemical Immunosensor to Assess Vaccine-Induced Antibody-Mediated Immunity against Wild-Type and Gamma SARS-CoV-2 Strains. <i>Biosensors</i> , 2023, 13, 371.	2.3	3
1219	Pseudotyped Viruses for Coronaviruses. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 133-151.	0.8	0
1220	Pseudotyped Viruses for Marburgvirus and Ebolavirus. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 105-132.	0.8	0
1221	Application of Pseudotyped Viruses. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 45-60.	0.8	2
1222	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
1223	Highly Selective Aptamer-Molecularly Imprinted Polymer Hybrids for Recognition of SARS-CoV-2 Spike Protein Variants. <i>Global Challenges</i> , 2023, 7, .	1.8	0

#	ARTICLE	IF	CITATIONS
1224	Myocarditis: causes, mechanisms, and evolving therapies. <i>Expert Opinion on Therapeutic Targets</i> , 2023, 27, 225-238.	1.5	4
1225	Design and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1226	COVID-19 Wireless Self-Assessment Software for Rural Areas in Nigeria. , 2023, , 213-222.		0
1227	A high-resolution melt curve toolkit to identify lineage-defining SARS-CoV-2 mutations. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
1228	In Silico Analysis of SARS-CoV-2 Spike Proteins of Different Field Variants. <i>Vaccines</i> , 2023, 11, 736.	2.1	1
1229	A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
1230	Enhanced Interfacial H-Bond Networks Promote Glycanâ€“Glycan Recognition and Interaction. <i>ACS Applied Materials & Interfaces</i> , 2023, 15, 17592-17600.	4.0	0
1231	Comprehensive deep mutational scanning reveals the pH induced stability and binding differences between SARS-CoV-2 spike RBD and human ACE2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 15207-15218.	2.0	1
1232	A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB. <i>Vaccines</i> , 2023, 11, 778.	2.1	1
1233	Germline-encoded amino acidâ€“binding motifs drive immunodominant public antibody responses. <i>Science</i> , 2023, 380, .	6.0	28
1234	Identification of B-Cell Linear Epitopes in the Nucleocapsid (N) Protein B-Cell Linear Epitopes Conserved among the Main SARS-CoV-2 Variants. <i>Viruses</i> , 2023, 15, 923.	1.5	3
1235	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0
1236	High-Affinity Neutralizing DNA Aptamers against SARS-CoV-2 Spike Protein Variants. <i>Covid</i> , 2023, 3, 520-542.	0.7	2
1237	Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. <i>Communications Biology</i> , 2023, 6, .	2.0	0
1238	High-throughput screening of spike variants uncovers the key residues that alter the affinity and antigenicity of SARS-CoV-2. <i>Cell Discovery</i> , 2023, 9, .	3.1	2
1239	Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	3
1240	Efficacy of Plant-Made Human Recombinant ACE2 against COVID-19 in a Golden Syrian Hamster Model. <i>Viruses</i> , 2023, 15, 964.	1.5	0
1241	Generation and Functional Analysis of Defective Viral Genomes during SARS-CoV-2 Infection. <i>MBio</i> , 2023, 14, .	1.8	5

#	ARTICLE	IF	CITATIONS
1242	Discovery of Highly Potent Small Molecule Pan-Coronavirus Fusion Inhibitors. <i>Viruses</i> , 2023, 15, 1001.	1.5	1
1252	Medical Perspective on COVID-19. <i>Contributions To Economics</i> , 2023, , 15-103.	0.2	0
1255	Comparative Analysis of SARS-CoV-2 Variants Across Three Waves in India. , 2023, , 104-118.		0
1293	Role of cellular fatty acids in combating the corona virus. , 2023, , 439-453.		0
1313	Research on Variation of Sars-Cov-2 and Rapid Detection. , 2023, , .		0
1327	Modeling Mutation-Driven Emergence of Drug-Resistance: A Case Study of SARS-CoV-2. <i>Fields Institute Communications</i> , 2023, , 161-174.	0.6	0
1345	A Data Analytics-Based Study in SARS-CoV-2 Genome Revealed a Commonality in the Infection Pattern. <i>Lecture Notes in Electrical Engineering</i> , 2024, , 173-184.	0.3	0